

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

## ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034114
Article Type:	Original research
Date Submitted by the Author:	07-Sep-2019
Complete List of Authors:	Jing, wenzhan; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Zhao, Siyu; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Jue; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Min; Peking University, School of Public Health, Department of Epidemiology & Biostatistics
Keywords:	Hepatitis B virus, ABO blood group, meta-analysis

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Title page**

2 **Title: ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis**

3 **Authors:** Wenzhan Jing <sup>†</sup>, Siyu Zhao <sup>†</sup>, Jue Liu <sup>\*</sup>, Min Liu <sup>\*</sup>

4 1 Wenzhan Jing, Department of Epidemiology and Biostatistics, School of Public Health, Peking

5 University; No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jingwenzhan@bjmu.edu.cn

6 2 Siyu Zhao, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

7 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: zhaosiyu@bjmu.edu.cn

8 3 Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

9 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jue Liu@bjmu.edu.cn

10 4 Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

11 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: liumin@bjmu.edu.cn

12 <sup>†</sup> WJ and SZ contributed equally to this work.

13  
14  
15 **Correspondence to:**

16 Prof. Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

17 Beijing 100191, China. (Tel: 86-10-82805146, Fax: 86-10-82805146, Email: liumin@bjmu.edu.cn);

18 Prof. Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

19 Beijing 100191, China. (Tel: 86-10-82801528, Fax: 86-10-82801528, Email: jue Liu@bjmu.edu.cn)

# 1 ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

## 2 Abstract

3 **Objective** Hepatitis B virus (HBV) infection is a major public health problem worldwide. Several studies  
4 have reported that ABO blood groups may be associated with HBV infection. However, its association is  
5 still controversial. Thus, we performed a meta-analysis to investigate whether ABO blood groups were  
6 associated with HBV infection.

7 **Design** Systematic review and meta-analysis.

8 **Data sources** Relevant studies available before December 1, 2017 were identified by searching PubMed,  
9 EMBASE, Web of Science, ScienceDirect, and the Cochrane Library.

10 **Eligibility criteria** All cross-sectional or cohort studies that the data of the ABO blood group distribution  
11 and HBV infection could be extracted.

12 **Data extraction and synthesis** Studies were identified and extracted by two reviewers independently.  
13 Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled by use of random-effects models to  
14 quantify this association.

15 **Results** Thirty-five eligible articles including 241,056 HBV-infected subjects and 6,236,375 uninfected  
16 subjects were included in this study. Overall, the risk of HBV infection had decreased by 8% in subjects  
17 with the blood group B when compared with the blood group non-B (RR = 0.92, 95% CI: 0.86–0.98),  
18 which was also observed in the subgroup analysis. In addition, subjects with blood group O had a 10%  
19 increased risk of HBV infection (RR = 1.10, 95% CI: 1.02–1.19), which was observed both in higher  
20 endemic areas (HBV prevalence  $\geq 5\%$ , RR = 1.16, 95% CI: 1.04–1.30) and in the Asian population (RR =  
21 1.15, 95% CI: 1.04–1.27). In the sensitivity analysis, the pooled risk estimates were still stable.

22 **Conclusions** Our data suggested that the blood group B was associated with a lower risk of HBV infection,  
23 while the blood group O was associated with a higher risk of HBV infection.

## 24 Strengths and limitations of this study

- 25 ➤ The breadth of the comprehensive systematic literature search is a strength of this study.
- 26 ➤ To our knowledge, this was the first meta-analysis of the association between ABO blood groups and  
27 HBV infection.

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 1 ➤ Although we performed subgroup analyses, the heterogeneity cannot be ignored because few  
2 published studies described the related risk factors of HBV infection in detail.

### 3 **Introduction**

4 Hepatitis B virus (HBV) infection is a major public health problem worldwide<sup>1</sup>, especially in Africa and  
5 the Western Pacific Region<sup>2</sup>. According to the global hepatitis report in 2017, it is estimated that 257  
6 million people, 3.5% of the general population, are living with HBV infection worldwide<sup>2</sup> with about 0.88  
7 million deaths caused by complications of chronic HBV infection every year<sup>2</sup>. HBV infection has caused  
8 a high societal burden globally<sup>1,2</sup>.

9 The ABO blood group system, the most extensively investigated erythrocyte antigen system<sup>3</sup>, is widely  
10 used in clinical practice, and influences the host susceptibility<sup>4,5</sup>. As an easily accessible factor in an  
11 individual's genetic makeup, ABO blood groups have been not only statistically but also biologically  
12 associated with many chronic diseases such as vascular disease<sup>6</sup>, coronary heart disease<sup>7</sup>, and  
13 tumorigenesis<sup>3,4,8</sup>. For example, O subjects have lower risk of venous thromboembolism (VTE) versus (vs.)  
14 non-O subjects because of a shorter von Willebrand factor (VWF) survival<sup>9</sup> due to A, B, and H antigens(  
15 H antigen is the biosynthetic precursor to A and B antigens<sup>5</sup>.) influence the half-life of the VWF by  
16 expressing on N-glycans of VWF<sup>9-11</sup>. Meanwhile, the association between ABO blood groups and host  
17 susceptibility to infectious diseases (such as helicobacter pylori, plasmodium falciparum, and human  
18 immunodeficiency virus, etc.) has been shown in several studies<sup>5,12</sup>. Previous studies have found the  
19 reasons for this association were that ABO antibodies are part of the innate immune system against some  
20 bacteria, parasites and enveloped viruses<sup>5</sup>, and blood antigens are important as receptors for immune and  
21 inflammation response<sup>13,14</sup>, which means the biologic association between ABO blood groups and HBV  
22 infection probably exist.

23 Epidemiologic studies have explored the relationship between blood group and HBV infection, however,  
24 the results have been contradictory. Lao et al.<sup>15</sup> found that HBV prevalence was lower in blood group B  
25 (9.6%) and AB (9.1%), but higher in blood group O (10.2%). Liu et al.<sup>16</sup> suggested that blood group O  
26 was associated with increased HBV infection. Mohammadali et al.<sup>17</sup> found that the percentage of hepatitis  
27 B surface antigen (HBsAg) was lower in donors who had blood group O. However, Szmuness et al.<sup>18,19</sup>  
28 and Behal et al.<sup>20</sup> failed to find a link between blood group and HBV infection. Thus, controversy remains  
29 with regard to whether blood group is related to HBV infection and which antigen is a protective or a risk

1 factor. We performed a systematic review and meta-analysis to elucidate the association between ABO  
2 blood groups and HBV infection risk to provide evidence on improving blood safety and preventing HBV  
3 infection, which can help to achieve the target of eliminating HBV as an international public health  
4 challenge<sup>21</sup>.

## 5 **Materials and methods**

### 6 **Data sources and search strategy**

7 Two reviewers (SZ and WJ) searched for articles, which were available online before December 1, 2017,  
8 from five databases including PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central  
9 using the following keywords: “hepatitis B” OR “hepatitis B virus” OR “HBV” OR “HBsAg” and “blood  
10 type” OR “blood group” OR “ABO” OR “Rh” OR “rhesus”. Meanwhile, highly relevant reference articles  
11 were also searched. There was no limitation of language or region.

### 12 **Inclusion and exclusion criteria**

13 Articles were included in the meta-analysis if: (1) the article was a cross-sectional or cohort study; (2) the  
14 data of the ABO blood group distribution and HBV infection could be extracted to calculate the risk ratio  
15 (RR), which meant that the number of HBV-infected and uninfected subjects were reported in each blood  
16 group. The exclusion criteria were as follows: (1) the article was not relevant to the subject of the study  
17 (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies,  
18 where if studies overlapped, we only included the last published; and (4) duplicated studies, where if the  
19 same study was found in different databases, we only included the article once.

20 According to the inclusion and exclusion criteria, studies were identified by two reviewers (SZ and WJ)  
21 independently. Discrepancies were solved by consensus or decided by a third reviewer (JL).

### 22 **Data extraction and quality assessment**

23 According to the piloted forms, four main parts of the information were extracted independently by two  
24 reviewers (SZ and WJ) from the selected studies: (1) the basic information of the studies including first  
25 author, publication year, journal, survey time, study design; (2) the characteristics of the study population  
26 including country, income group, race, population type (e.g., blood donors, patients, general population),  
27 sample size, the number of HBV-infected and uninfected subjects, age range, mean age, sex ratio; (3) the

1 outcome measure: the number of HBV-infected and uninfected subjects in each ABO blood group; and  
2 (4) the author's general conclusions.

3 The quality of selected cohort studies were assessed using the Newcastle-Ottawa Scales (NOS) with a  
4 score ranging from 0 to 9<sup>22</sup>. A score of 4–6 indicated moderate quality, and a score of 7–9 indicated high  
5 quality. The quality of the selected cross-sectional studies were assessed using an 11-item checklist  
6 recommended by the Agency for Healthcare Research and Quality (AHRQ)<sup>23</sup> with a score ranging from 0  
7 to 11. A score of 4–7 indicated moderate quality, and a score of 8–11 indicated high quality.

### 8 **Statistical analysis**

9 The main outcome was the prevalence of HBV infection (defining as HBsAg-positive) in our meta-  
10 analysis. The relationship between the ABO blood groups and HBV infection was quantified using RR  
11 values and the corresponding 95% confidence intervals (CIs). RRs and 95% CIs (A vs. non-A, B vs. non-B,  
12 O vs. non-O, AB vs. non-AB) were pooled by use of random-effects models. Meanwhile,  $I^2$  was used to  
13 evaluate heterogeneity among the studies. When  $I^2 \leq 50\%$ , the included studies were considered to have  
14 little heterogeneity; when  $I^2 > 50\%$ , the included studies were considered to have substantial  
15 heterogeneity<sup>24</sup>.

16 Subgroup analyses were performed by HBV prevalence, race, sample size, population, income group,  
17 study type, and publication year. The prevalence of HBV infection was calculated in each study based on  
18 the number of HBV-infected and uninfected subjects. Studies were divided into Caucasian, Asian, and  
19 Black subgroups depending on the major national race and divided into high, upper middle, lower middle  
20 and low income groups according to the World Bank list of economies<sup>25</sup>. Sensitivity analyses were  
21 performed by excluding the study which dominated the results of the meta-analysis. Publication bias was  
22 evaluated by funnel plots and Egger's tests. All statistical analyses were performed with STATA version  
23 12.0.

### 24 **Patient and public involvement**

25 There was no direct patient or public involvement in this review.

## 26 **Results**

### 27 **Study selection and study characteristics**



1 A total of 3836 articles (3826 from database and 10 from other sources) were searched, of which 1182  
2 were duplicate results. After reading the abstracts, 2015 were deemed irrelevant and three reviews were  
3 excluded. After reading the full text, 601 articles were excluded, of which 564 were irrelevant articles, and  
4 37 studies provided insufficient information. Eventually, 35 eligible articles were included in the meta-  
5 analysis. A flow-chart of study selection was generated according to the PRISMA requirements (Figure  
6 1).

7  
8 **Insert Figure 1.** The process of study selection for the meta-analysis.

9  
10 The basic characteristics of the selected studies are shown in Table 1 (More details are shown in  
11 Additional file 1). All selected articles were observational studies and published between 1970 and 2017.  
12 A total of 6,477,431 subjects were included with 241,056 HBV-infected subjects and 6,236,375 uninfected  
13 subjects. Among the Caucasian, Asian, and Black population, there were 23, six, and six studies,  
14 respectively. In addition, there were seven, seven, 17 and four study in high income, upper middle income,  
15 lower middle income and low income group, respectively. Furthermore, there were 12 studies in higher  
16 (HBV prevalence  $\geq 5\%$ ) endemic and 23 studies in lower (HBV prevalence  $<5\%$ ) endemic areas,  
17 respectively. Meanwhile, there were 34 cross-sectional studies and one cohort study in the meta-analysis.

18

**Table 1.** Characteristics of the included studies.

Author	Income group	Race	Population	Sample size	HBV infection (n/%)				
					Total	A, non-A <sup>a</sup>	B, non-B <sup>a</sup>	AB, non-AB <sup>a</sup>	O, non-O <sup>a</sup>
Terrier, E.1970 <sup>26</sup>	High	Caucasian	Blood donors	5968	55/0.92	9/0.37, 46/1.31	4/0.66, 51/0.95	2/0.78, 53/0.93	40/1.51, 15/0.45
Leski, M.1970 <sup>27</sup>	High	Caucasian	Patients	155	34/21.94	16/23.19, 18/20.93	4/28.57, 30/21.28	0/0, 34/22.67	14/20.9, 20/22.73
Szmunness, W.1971 <sup>18</sup>	High	Caucasian	Blood donors	8096	177/2.19	61/2.06, 116/2.26	25/2.21, 152/2.18	13/3.57, 164/2.12	78/2.14, 99/2.23
Zuberi, S. J.1974 <sup>28</sup>	Lower middle	Caucasian	Blood donors	1111	38/3.42	9/3.36, 29/3.44	5/1.23, 33/4.69	2/3.64, 36/3.41	22/5.77, 16/2.19
Vale, T. G.1974 <sup>29</sup>	Lower middle	Black	General	836	40/4.78	18/5.61, 22/4.27	6/4.11, 34/4.93	5/4.59, 35/4.81	11/4.23, 29/5.03
Moore, H. H.1975 <sup>30</sup>	Low	Caucasian	Blood donors	14916	495/3.32	127/3.48, 368/3.27	103/3.21, 392/3.35	17/3.1, 478/3.33	248/3.3, 247/3.33
Szmunness, W.1975 <sup>19</sup>	High	Caucasian	Blood donors	51019	58/0.11	22/0.11, 36/0.11	5/0.08, 53/0.12	4/0.16, 54/0.11	27/0.12, 31/0.11
Lenka, M. R.1981 <sup>31</sup>	Lower middle	Caucasian	Blood donors	500	24/4.8	12/9.3, 12/3.23	8/4.08, 16/5.26	0/0, 24/5.25	4/3.03, 20/5.43
Nath, N.1985 <sup>32</sup>	Lower middle	Caucasian	Blood donors	1585	68/4.29	22/4.03, 46/4.44	9/3.35, 59/4.48	3/4.17, 65/4.30	34/4.87, 34/3.83
Kulkarni, A. G.1986 <sup>33</sup>	Lower middle	Black	Blood donors	1860	165/8.87	51/13.11, 114/7.85	17/3.11, 148/11.27	18/18.75, 147/8.33	79/9.54, 86/8.33
Naidu, A. S.1986 <sup>34</sup>	High	Caucasian	Blood donors	1029	145/14.09	49/20.08, 96/12.40	42/12.39, 103/14.93	11/17.74, 134/13.86	43/11.20, 102/15.81
Sebastian, V. J.1989 <sup>35</sup>	Upper middle	Asian	Blood donors	3276	134/4.09	30/4.17, 104/4.08	30/3.50, 104/4.30	10/4.76, 124/4.04	64/4.30, 70/3.91
Zhu, C.2002 <sup>36</sup>	Low	Asian	Blood donors	8683	153/1.76	44/1.62, 109/1.83	30/1.37, 123/1.89	18/2.59, 135/1.69	61/1.98, 92/1.64
Joshi, S. K.2003 <sup>37</sup>	Lower middle	Asian	General	613	17/2.77	4/2.09, 13/3.08	5/2.86, 12/2.74	1/2.13, 16/2.83	7/3.5, 10/2.42
El-Gilany, A-H.2006 <sup>38</sup>	Lower middle	Caucasian	Blood donors	2157	93/4.31	27/3.42, 66/4.87	19/3.85, 74/4.45	12/5.88, 81/4.15	35/5.23, 58/3.90
Behal, R.2008 <sup>20</sup>	Lower middle	Caucasian	Blood donors	20000	450/2.25	106/2.30, 344/2.24	174/2.34, 276/2.20	38/1.87, 412/2.29	132/2.23, 318/2.26
Rifat-uz-Zaman2009 <sup>39</sup>	Lower middle	Caucasian	General	1464	93/6.35	5/3.01, 88/6.90	35/6.63, 58/6.20	23/6.99, 70/6.17	30/6.80, 63/6.16
Dirisu, J. O.2011 <sup>40</sup>	Lower middle	Black	Blood donors	427	200/46.84	32/45.71, 168/47.06	39/52, 161/45.74	1/33.33, 199/46.93	128/45.88, 72/48.65
Saeed Anwar, M.2011 <sup>41</sup>	Upper middle	Caucasian	Blood donors	16695	467/2.80	103/2.60, 364/2.86	139/2.31, 328/3.07	17/2.64, 450/2.80	208/3.42, 259/2.44
Omar, A. A. 2012 <sup>42</sup>	Lower middle	Caucasian	Blood donors	430	71/16.51	15/12.5, 56/18.06	21/21.43, 50/15.06	3/5.36, 68/18.18	32/20.51, 39/14.23
Tyagi, S.2013 <sup>43</sup>	Lower middle	Caucasian	Blood donors	6000	95/1.58	27/1.87, 68/1.49	27/1.27, 68/1.75	9/1.98, 86/1.55	32/1.62, 63/1.57
Sethi, B.2014 <sup>44</sup>	Upper middle	Caucasian	Blood donors	7884	50/0.63	15/0.60, 35/0.65	10/0.41, 40/0.74	11/1.28, 39/0.56	14/0.68, 36/0.62
Mohammadali, F.2014 <sup>17</sup>	Lower middle	Caucasian	Blood donors	2028068	7839/0.39	2553/0.40, 5286/0.38	1952/0.40, 5887/0.38	627/0.41, 7212/0.38	2707/0.36, 5132/0.40
Nigam, J. S.2014 <sup>45</sup>	High	Caucasian	Blood donors	4128	40/0.97	12/1.17, 28/0.90	11/0.75, 29/1.09	2/0.50, 38/1.02	15/1.22, 25/0.86
Lao, T. T.2014 <sup>15</sup>	Upper middle	Asian	General	78705	7786/9.89	2038/9.90, 5748/9.97	1991/9.60, 5795/10.00	468/9.11, 7318/9.95	3289/10.20, 4497/9.68
Zhao, Y.2014 <sup>46</sup>	Lower middle	Asian	Patients	500	66/13.20	17/11.18, 49/14.71	16/9.82, 50/14.84	15/16.67, 51/12.44	18/18.95, 48/11.85
Siransy, L. K.2015 <sup>47</sup>	Lower middle	Black	Blood donors	59514	4119/6.92	947/7.15, 3172/6.86	941/6.78, 3178/6.96	187/6.77, 3932/6.93	2044/6.9, 2075/6.94
Navolan, D.2015 <sup>48</sup>	Upper middle	Caucasian	General	1385	33/2.38	15/2.42, 18/2.37	7/3.11, 26/2.24	4/3.54, 29/2.28	7/1.64, 26/2.71
Bisetegen, F. S.2016 <sup>49</sup>	Lower middle	Black	Blood donors	390	37/9.49	7/6.73, 30/10.49	10/12.99, 27/8.63	2/22.22, 35/9.19	18/9, 19/10
Abate, M.2016 <sup>30</sup>	Upper middle	Black	Blood donors	6827	647/9.48	114/5.66, 533/11.10	54/5.45, 593/10.16	9/4.27, 638/9.64	470/13.02, 177/5.50
Bharadva, S.2016 <sup>51</sup>	Lower middle	Caucasian	Blood donors	41909	237/0.57	62/0.63, 175/0.55	85/0.58, 152/0.56	22/0.55, 215/0.57	68/0.51, 169/0.59
Naseri, Z.2016 <sup>52</sup>	High	Caucasian	Blood donors	228409	640/0.28	208/0.29, 432/0.28	180/0.34, 460/0.26	42/0.24, 598/0.28	210/0.25, 430/0.30
Memon, F. A.2017 <sup>53</sup>	Lower middle	Caucasian	Blood donors	4683	66/1.41	15/1.37, 51/1.42	21/1.53, 45/1.36	9/2.94, 57/1.30	21/1.10, 45/1.63
Liu, J.2017 <sup>16</sup>	Lower middle	Asian	General	3827125	215455/5.63	64811/5.55, 150644/5.71	58286/5.18, 157169/5.82	18707/5.06, 196748/5.69	73651/6.34, 141804/5.32
Batool, Z.2017 <sup>54</sup>	Low	Caucasian	Blood donors	41084	969/2.36	321/2.72, 648/2.22	289/2.21, 680/2.43	82/2.13, 887/2.38	277/2.24, 692/2.41

<sup>a</sup> The number of HBV infected people in the X blood group/HBV prevalence (%) in the X blood group; the number of HBV infected people in the non-X blood group/HBV prevalence (%) in the non-X blood group.

2  
3

1 The HBV infection prevalence in the 35 eligible articles ranged from 0.11% to 46.84%, and the HBV  
2 infection prevalence of blood group A, B, AB, O ranged from 0.11% to 45.71%, 0.08% to 52.00%, 0.00%  
3 to 33.33%, and 0.12% to 45.88%, respectively. The results of the quality assessment are shown in  
4 Additional file 2, with 13 high quality studies and 22 moderate quality studies. The score of the 34 articles  
5 assessed by AHRQ ranged from 3 to 9, while 12 of them were of high-quality with a score from 8 to 9,  
6 and 22 of them were of moderate-quality with a score from 4 to 7. The article assessed by NOS scored 7  
7 and was of high-quality.

### 8 **Main, subgroup, and sensitivity analyses**

9 Overall, the risk of HBV infection had decreased by 8% in subjects with blood group B when compared  
10 with blood group non-B (RR = 0.92, 95% CI: 0.86–0.98), while the risk of HBV infection had increased  
11 by 10% in subjects with blood group O when compared with blood group non-O (RR = 1.10, 95% CI:  
12 1.02–1.19) (Table 2). However, blood groups A and AB were not significantly associated with an HBV  
13 infection risk (Table 2).

1

2 **Table 2.** The main, subgroup and sensitivity analyses.

Subgroup	No. of studies	B vs. Non-B		O vs. Non-O		A vs. Non-A		AB vs. Non-AB		
		RR (95% CI)	P value	RR (95% CI)	P value	RR (95% CI)	P value	RR (95% CI)	P value	
All studies	35	0.92 (0.86,0.98)	0.009	1.10 (1.02,1.19)	0.020	1.00 (0.94, 1.06)	0.987	1.03 (0.94,1.13)	0.493	
HBV prevalence										
Higher endemic ( $\geq 5\%$ )	12	0.89 (0.82,0.98)	0.018	1.16 (1.04,1.30)	0.007	0.96 (0.88,1.06)	0.459	0.99 (0.87,1.13)	0.864	
Lower endemic ( $<5\%$ )	23	0.93 (0.85,1.02)	0.126	1.06 (0.95,1.17)	0.306	1.03 (0.95,1.11)	0.471	1.06 (0.95,1.18)	0.292	
Race										
Caucasian	23	0.96 (0.87, 1.05)	0.386	1.04 (0.94, 1.16)	0.465	1.03 (0.94, 1.13)	0.472	1.05 (0.93, 1.18)	0.461	
Asian	6	0.91(0.85, 0.97)	0.003	1.15 (1.04, 1.27)	0.008	0.98 (0.97, 0.99)	0.000	0.93 (0.85, 1.01)	0.077	
Black	6	0.76 (0.53, 1.10)	0.144	1.15 (0.79, 1.67)	0.456	0.96 (0.67, 1.36)	0.806	1.08 (0.65, 1.80)	0.760	
Sample size										
$\geq 2000$	21	0.93 (0.87, 0.99)	0.025	1.10 (1.01, 1.21)	0.030	0.98 (0.93, 1.04)	0.516	0.99 (0.91, 1.08)	0.759	
$<2000$	14	0.85 (0.64, 1.13)	0.275	1.08 (0.90, 1.29)	0.398	1.07 (0.85, 1.33)	0.577	1.20 (0.89, 1.61)	0.238	
Population										
General	6	0.93 (0.87, 0.99)	0.016	1.11 (0.99, 1.24)	0.078	0.98 (0.96, 1.00)	0.035	0.89 (0.88, 0.90)	0.000	
Blood donors	27	0.89 (0.81, 0.98)	0.013	1.11 (0.99, 1.23)	0.070	1.00 (0.91, 1.10)	0.990	1.08 (0.95, 1.23)	0.218	
Patients	2	0.86 (0.44, 1.70)	0.666	1.25 (0.73, 2.14)	0.422	0.92 (0.62, 1.36)	0.663	1.28 (0.76, 2.14)	0.357	
Income group										
High	7	0.96 (0.91,1.00)	0.065	1.17 (0.95,1.44)	0.135	0.91 (0.74,1.11)	0.343	0.97 (0.84,1.13)	0.712	
Upper middle	7	1.01 (0.88,1.17)	0.857	1.06 (0.89, 1.28)	0.512	1.00 (0.95,1.05)	0.981	0.99 (0.85,1.16)	0.943	
Lower middle	17	0.86 (0.75,0.97)	0.014	1.03 (0.93,1.14)	0.630	1.12 (1.00,1.26)	0.044	1.14 (0.96,1.35)	0.142	
Low	4	0.88 (0.56,1.38)	0.572	1.34 (0.72, 2.48)	0.353	0.71 (0.42,1.21)	0.209	0.84 (0.43,1.64)	0.613	
Study design										
Cross-sectional	34	0.91 (0.84, 0.98)	0.009	1.10 (1.01, 1.20)	0.031	1.00 (0.93,1.07)	0.958	1.06 (0.96, 1.17)	0.279	
Cohort	1	0.96 (0.92, 1.01)	0.098	1.05 (1.01, 1.10)	0.016	1.00 (0.95, 1.05)	0.957	0.92 (0.84, 1.00)	0.053	
Publication year										
Before 2010	17	0.80 (0.67, 0.96)	0.015	1.12 (0.97, 1.29)	0.112	1.02 (0.85, 1.22)	0.830	1.22 (1.01, 1.46)	0.040	
After 2010	18	0.95 (0.88, 1.02)	0.146	1.09 (0.99, 1.20)	0.095	0.98 (0.93, 1.05)	0.601	0.97 (0.88, 1.06)	0.478	
Sensitive analyses										
Removed Liu's study	34	0.91 (0.84, 0.98)	0.015	1.09 (1.00, 1.19)	0.041	1.00 (0.92, 1.08)	0.941	1.06 (0.96, 1.18)	0.242	
Removed Mohammedali's study	34	0.91 (0.85, 0.97)	0.003	1.11 (1.03, 1.20)	0.008	0.99 (0.93, 1.06)	0.875	1.03 (0.94, 1.13)	0.526	

3 RR: Risk ratio.

4

5 The results of the subgroup analyses are shown in Table 2. In the subgroup analyses, the relationship  
6 between blood group B and HBV infection remained stable. The inverse relationship between blood group  
7 B and HBV infection was still observed in the higher endemic areas (HBV prevalence  $\geq 5\%$ ), Asian  
8 people, studies with larger sample sizes ( $\geq 2000$ ), general population and blood donors, lower middle  
9 income group, and articles published before 2010 years (Table 2). In addition, the relationship between  
10 blood group O and HBV infection also remained stable in the higher endemic areas (HBV prevalence  $\geq$   
11 5%), Asian people, studies with larger sample sizes ( $\geq 2000$ ) (Table 2).

1 In higher endemic areas, subjects with blood group B had a significantly lower risk of HBV infection  
2 (RR = 0.89, 95% CI: 0.82–0.98) than the non-B group (Figure 2A), while subjects with the blood group  
3 O had a significantly higher risk of HBV infection (RR = 1.16, 95% CI: 1.04–1.30) than the non-O group  
4 (Figure 2B). According to the race of the subjects, blood group O was also found to be linked with an  
5 increased risk of HBV infection (RR = 1.15, 95% CI: 1.04–1.27) in the Asian population, while blood  
6 groups A and B were linked with decreased risk of HBV infection when compared to non-A and non-B,  
7 respectively (OR = 0.91, 95%CI: 0.85–0.97; OR = 0.98, 95% CI: 0.97–0.99) (Table 2). However, no  
8 association was found among the Caucasian or Black population.

9  
10 **Insert Figure 2.** Forest plots by prevalence: (A) B vs. non-B; (B) O vs. non-O.

11  
12 In the sensitivity analysis, when the study of Jue Liu and Fatemeh Mohammadali, which dominated the  
13 results of the meta-analysis, were orderly removed, the pooled risk estimates were still stable (Table 2).

#### 14 **Publication bias**

15 Funnel plots and Egger's tests were performed to assess publication bias. No obvious evidence of  
16 publication bias was present for A vs. non-A, B vs. non-B, and O vs. non-O ( $P = 0.219$ ;  $P = 0.238$ ;  $P =$   
17  $0.537$ , respectively), while a publication bias of AB vs. non-AB was observed ( $P = 0.002$ ) (Figure 3).

18 **Insert Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

#### 19 20 **Discussion**

21 To our knowledge, this was the first meta-analysis of the association between ABO blood groups and HBV  
22 infection. Our meta-analysis results suggested that blood group B was associated with a lower risk of HBV  
23 infection, while blood group O was associated with a higher risk of HBV infection. The relationship  
24 between ABO blood group and HBV infection was observed in several subgroups, especially in higher  
25 endemic areas and in the Asian population, which gave supportive evidence that not only statistical  
26 association but also biologic association between ABO blood groups and HBV infection probably exists.

27 As an infectious disease, aside from genetic susceptibility factors, there is the question of whether  
28 exposure to the source of infection is directly related to the risk of infection. People living in higher

1  
2 1 endemic areas are at higher risk of exposure to HBV than those living in lower endemic areas, which might  
3  
4 2 be the reason why the association between ABO blood group and HBV infection was only found in higher  
5  
6 3 endemic areas but not in lower endemic areas.

7  
8 4 The implementation of universal hepatitis B vaccination program for newborns was started in 1992  
9  
10 5 proposed by WHO. All the selected articles were published between 1970 and 2017, which meant that  
11  
12 6 even in the same country, the prevalence of HBV infection has changed significantly due to increasing  
13  
14 7 coverage of hepatitis B vaccination. However, no enough information could be extracted from the previous  
15  
16 8 studies to compare the pooled association of ABO blood group and HBV infection between vaccinated  
17  
18 9 group and unvaccinated group. To partially examine the impact of hepatitis B vaccination on the results,  
19  
20 10 we did subgroup analyses according to publication year before and after 2010. Subjects in the selected  
21  
22 11 articles were mainly people over 18 years old. Thus, subjects in articles published after 2010 were more  
23  
24 12 likely to be vaccinated at the time of birth, while subjects were mostly not vaccinated at birth in the articles  
25  
26 13 published before 2010. We observed the association of blood group B and HBV infection in the articles  
27  
28 14 published before 2010 rather than after 2010. The gradual establishment of an HBV immune barrier in the  
29  
30 15 population may affect the occurrence of the relationship between ABO blood type and HBV infection.

31  
32 16 Our results were consistent with some previous studies of Lao et al.<sup>15</sup>, Liu et al.<sup>16</sup> and Abate et al.<sup>50</sup> in  
33  
34 17 high endemic areas, which showed that participants with blood group O were at higher risk of HBV  
35  
36 18 infection. That means more measures should be taken to ensure the “universal” group-O blood safety in  
37  
38 19 high endemic areas because of the large unvaccinated population among the main blood donors in current  
39  
40 20 era and the window period for detection among the HBV-infected blood donors.<sup>16</sup> Interestingly, our result  
41  
42 21 that blood group B was associated with a lower risk of HBV infection compared with blood group non-B  
43  
44 22 was few reported explicitly by other studies, possibly because of the different analysis methods.

45  
46 23 However, the study of Mohammadali et al.<sup>17</sup>, with the second largest sample size, reported that HBV  
47  
48 24 infection was lower in group-O donors, opposing to the study with the largest sample by Liu et al.,<sup>16</sup>  
49  
50 25 probably due to the different geography and ethnicity. To examine the reliable and stable of the results,  
51  
52 26 we orderly removed the study of Liu et al.<sup>16</sup> or Mohammadali et al.<sup>17</sup>, and the results were still stable.  
53  
54 27 Therefore, we still thought that these findings were worthy of consideration due to the subgroup analyses,  
55  
56 28 the sensitive analyses and the relatively conservative random effects model.

57  
58 29 Although the precise role that ABO blood groups play in host susceptibility and HBV infection has yet  
59  
60 30 to be clarified<sup>16</sup>, associations have been observed most likely related to the altered immune response<sup>15</sup> and

1 systemic inflammatory response<sup>14</sup> associated with different blood group phenotypes. A previous study has  
2 reported that the appearance of intestinal alkaline phosphatase in the plasma was associated with the ABO  
3 blood group and secretor status, which may be due to genetically determined variations in the proportion  
4 of isoenzymes among the different blood types<sup>55</sup>. Our study may indicate that specific histo-bloodgroup  
5 antigen may be a natural resistance factor for HBV infection, and that probably provides clues for  
6 correlative fundamental researches of etiologies and novel therapeutic targets for HBV. Further studies  
7 are warranted to elucidate the association between blood group and HBV infection, and the way the blood  
8 type influences the process of HBV infection.

9 Meanwhile, several limitations need to be considered. First, although we performed subgroup analyses,  
10 analyses of previous studies have revealed that the heterogeneity cannot be ignored. Second, the analyzed  
11 studies lacked the basic information of the ethnicity data and the prevalence of different HBV genotypes.  
12 Third, few published studies on the association between HBV infection and blood group have controlled  
13 HBV infection related risk factors such as family history of HBV infection, blood transfusion, and  
14 acupuncture, thus we were not able to conduct the corresponding subgroup analyses.

15 In conclusion, blood group B was associated with a lower risk of HBV infection, while blood group O  
16 was associated with a higher risk of HBV infection, especially in higher endemic areas and in the Asian  
17 population. Therefore, individuals with blood group O should be given more attention to reduce the  
18 incidence rate of HBV infection, particularly in clinical practice to ensure the safety of blood for recipients.  
19 Furthermore, more researches are needed to clarify the precise role of the ABO blood group in HBV  
20 infection to address the global question of HBV infection.

## 22 **Supplementary**

23 Additional file 1: Extracted Data from Included Studies. The number of HBV-infected and uninfected  
24 subjects in each blood group is provided.

25 Additional file 2: Quality assessment tables.

27 **Abbreviations** HBV, Hepatitis B virus; OR, odds ratio; CI, confidence interval; VTE, venous  
28 thromboembolism; vs., versus; VWF, von Willebrand factor; HBsAg, hepatitis B surface antigen; Rh,

1 rhesus; RR, risk ratio; NOS, Newcastle-Ottawa Scales; AHRQ, Agency for Healthcare Research and  
2 Quality.  
3  
4  
5  
6  
7

8 **Contributions** All authors contributed to this work. ML and JL conceived and designed the study strategy;  
9  
10 SZ and WJ independently completed the processes of the article search, article assessment, data extraction,  
11 quality assessment, and data analysis; and WJ wrote the manuscript. All authors read and approved the final  
12 manuscript.  
13  
14

15 **Funding** This study was supported by the National Natural Science Foundation of China (Grant No. 71874003  
16 and No. 81703240).  
17  
18

19 **Competing interests** The authors declare that they have no competing interests.  
20

21 **Patient consent for publication** Not required.  
22

23 **Provenance and peer review** Not commissioned; externally peer reviewed.  
24

25 **Availability of data and material** All data generated or analyzed during this study are included in this  
26 published article and its supplementary information files.  
27  
28

29 **Open access** This is an open access article distributed in accordance with the Creative Commons Attribution  
30 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon  
31 this work for any purpose, provided the original work is properly cited, a link to the licence is given, and  
32 indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.  
33  
34

## 35 REFERENCES


- 36 1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. *Lancet* 2014; **384**(9959): 2053-63.
- 37 2. WHO. Global hepatitis report, 2017. 2017. <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/#>.
- 38 3. Li B, Tan B, Chen C, Zhao L, Qin L. Association between the ABO blood group and risk of  
39 common cancers. *J Evid Based Med* 2014; **7**(2): 79-83.
- 40 4. Wang W, Liu L, Wang Z, et al. ABO blood group and esophageal carcinoma risk: from a case-  
41 control study in Chinese population to meta-analysis. *Cancer Causes Control* 2014; **25**(10): 1369-77.
- 42 5. Cooling L. Blood Groups in Infection and Host Susceptibility. *Clin Microbiol Rev* 2015; **28**(3): 801-  
43 70.
- 44 6. Alpoim PN, de Barros Pinheiro M, Junqueira DR, et al. Preeclampsia and ABO blood groups: a  
45 systematic review and meta-analysis. *Mol Biol Rep* 2013; **40**(3): 2253-61.
- 46 7. He M, Wolpin B, Rexrode K, et al. ABO blood group and risk of coronary heart disease in two  
47 prospective cohort studies. *Arterioscler Thromb Vasc Biol* 2012; **32**(9): 2314-20.
- 48 8. Miao SY, Zhou W, Chen L, Wang S, Liu XA. Influence of ABO blood group and Rhesus factor  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



- 1 on breast cancer risk: a meta-analysis of 9665 breast cancer patients and 244,768 controls. *Asia Pac J*  
2 *Clin Oncol* 2014; **10**(2): 101-8.
- 3 9. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O  
4 blood group subjects explains how ABO determinants influence plasma von Willebrand factor. *Blood*  
5 2008; **111**(7): 3540-5.
- 6 10. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a  
7 biologic function after all? *Transfusion* 2006; **46**(10): 1836-44.
- 8 11. Anstee DJ. The relationship between blood groups and disease. *Blood* 2010; **115**(23): 4635-43.
- 9 12. Branch DR. Blood groups and susceptibility to virus infection: new developments. *Curr Opin*  
10 *Hematol* 2010; **17**(6): 558-64.
- 11 13. Pare G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with  
12 soluble ICAM-1: results of a genome-wide association study of 6,578 women. *PLoS Genet* 2008; **4**(7):  
13 e1000118.
- 14 14. Zhou Y, Zhou Q, Lin Q, et al. Evaluation of risk factors for extrahepatic cholangiocarcinoma:  
15 ABO blood group, hepatitis B virus and their synergism. *Int J Cancer* 2013; **133**(8): 1867-75.
- 16 15. Lao TT, Sahota DS, Chung MK, Cheung TK, Cheng YK, Leung TY. Maternal ABO and rhesus  
17 blood group phenotypes and hepatitis B surface antigen carriage. *J Viral Hepat* 2014; **21**(11): 818-23.
- 18 16. Liu J, Zhang S, Liu M, Wang Q, Shen H, Zhang Y. Distribution of ABO/Rh blood groups and  
19 their association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based  
20 cross-sectional study. *J Viral Hepat* 2018; **25**(4): 401-11.
- 21 17. Mohammadali F, Pourfathollah A. Association of ABO and Rh Blood Groups to Blood-Borne  
22 Infections among Blood Donors in Tehran-Iran. *Iran J Public Health* 2014; **43**(7): 981-9.
- 23 18. Szmuness W, Prince AM, Cherubin CE. Serum hepatitis antigen (SH) carrier state: relation to  
24 ABO blood groups. *Br Med J* 1971; **2**(5755): 198-9.
- 25 19. Szmuness W, Hirsch RL, Prince AM, Levine RW, Harley EJ, Ikram H. Hepatitis B surface antigen  
26 in blood donors: further observations. *J Infect Dis* 1975; **131**(2): 111-8.
- 27 20. Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. Seroprevalence and risk factors  
28 for hepatitis B virus infection among general population in Northern India. *Arq Gastroenterol* 2008;  
29 **45**(2): 137-40.
- 30 21. WHO. Global health sector strategy on viral hepatitis 2016-2021. 2016.  
31 <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>.
- 32 22. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of  
33 nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**(9): 603-5.
- 34 23. Rostom A, Dube C, Cranney A, et al. Agency for Healthcare Research and Quality (US). 2004 Sep.  
35 <https://www.ncbi.nlm.nih.gov/books/NBK35156/>.
- 36 24. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**(11):  
37 1539-58.
- 38 25. World Bank. World Bank list of economies (July 2016). 2016.  
39 <http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS>.
- 40 26. Terrier E, Simonneau M, Jaulmes B. Screening blood donors for Australia antigen carriers at the  
41 Broussais hospital. *Vox Sang* 1970; **19**(3): 352-6.
- 42 27. Leski M, Grivaux C, Courouce-Pauty AM. Australia antigen in hemodialysis and renal  
43 transplantation units. *Vox Sang* 1970; **19**(3): 359-68.
- 44 28. Zuberi SJ, Lodi TZ. Hepatitis B antigen in blood donors in Karachi. 1974. *J Pak Med Assoc* 2004;

- 1 54(8 Suppl): S39-40.
- 2 29. Vale TG, Thomas HN, Hawkes RA, Kelly A. ABO blood groups and hepatitis B antigen and  
3 antibody. *Aust N Z J Med* 1974; **4**(1): 1-2.
- 4 30. Moore HH, Campling M, Hart GE. A comparison of hepatitis B antigen and blood groups in  
5 African donors. *Cent Afr J Med* 1975; **21**(8): 175-6.
- 6 31. Lenka MR, Ghosh E, Bhattacharyya PK. ABO blood groups in relation to hepatitis-B surface  
7 antigen (Australia antigen). *Trans R Soc Trop Med Hyg* 1981; **75**(5): 688-90.
- 8 32. Nath N, Mushahwar IK, Fang CT, Berberian H, Dodd RY. Antibodies to Delta-Antigen in  
9 Asymptomatic Hepatitis-B Surface Antigen-Reactive Blood-Donors in the United-States and Their  
10 Association with Other Markers of Hepatitis-B Virus. *Am J Epidemiol* 1985; **122**(2): 218-25.
- 11 33. Kulkarni AG, Aloowooja FO, Wayo GB. Prevalence of hepatitis B surface antigen in northern  
12 Nigerian blood donors. *Vox Sang* 1986; **50**(3): 151-3.
- 13 34. Naidu AS, Rajyalakshmi K. Detection of hepatitis B surface antigen among professional blood  
14 donors in Hyderabad, India. *J Commun Dis* 1986; **18**(3): 215-8.
- 15 35. Sebastian VJ, Bhattacharya S, Ray S, Ahmad MZ. Hepatitis-B surface antigen and VDRL in  
16 healthy blood donors of Brunei Darussalam. *Singapore Med J* 1989; **30**(6): 568-70.
- 17 36. Zhu C, Zhang H, Xiong J, Gan D. Study on Relationship between ABO Blood-Type and Infection  
18 of Hepatitis Viruses. *Acta Acad Med Jiangxi* 2002; **42**: 72-3.
- 19 37. Joshi SK, Ghimire GR. Serological prevalence of antibodies to human immunodeficiency virus  
20 (HIV) and hepatitis B virus (HBV) among healthy Nepalese males--a retrospective study. *Kathmandu  
21 Univ Med J* 2003; **1**(4): 251-5.
- 22 38. El-Gilany A-H, El-Fedawy S. Bloodborne infections among student voluntary blood donors in  
23 Mansoura University, Egypt. *East Mediterr Health J* 2006; **12**(6): 742-8.
- 24 39. Rifat-uz-Zaman. Relationship between HBV-markers prevalence and promotive factors among  
25 human urban population of Bahawalpur district, Pakistan: A cross-sectional study. *Res J Pharmacol*  
26 2009; **3**(1): 7-14.
- 27 40. Dirisu JO, Alli TO, Adegoke AO, Osazuwa F. A Survey of prevalence of serum antibodies to  
28 human immunodeficiency deficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus  
29 (HCV) among blood donors. *N Am J Med Sci* 2011; **3**(1): 35-8.
- 30 41. Saeed Anwar M, Mujtaba Siddiqi G, Haq S, Ghias Khokhar N, Jaffery G. Association of blood  
31 group types to hepatitis B and hepatitis C virus infection. *Biomedica* 2011; **27**:57-61.
- 32 42. Omar AA, Noor NA, Mahmood JM. The infection with HBV and HCV and their relationship to  
33 ABO blood group among blood donors. *J Fac Med Baghdad* 2012; **54**(1): 52-6.
- 34 43. Tyagi S, Tyagi A. Possible Correlation of Transfusion Transmitted Diseases with Rh type and  
35 ABO Blood Group System. *J Clin Diagn Res* 2013; **7**(9): 1930-1.
- 36 44. Sethi B, Kumar S, Butola KS, Mishra JP, Kumar Y. Seroprevalence pattern among blood donors  
37 in a tertiary health care center. *Internet J Med Update* 2014; **9**(1): 10-5.
- 38 45. Nigam JS, Singh S, Kaur V, Giri S, Kaushal RP. The Prevalence of Transfusion Transmitted  
39 Infections in ABO Blood Groups and Rh Type System. *Hematol Rep* 2014; **6**(4): 5602.
- 40 46. Zhao Y, Zhang Y, Huang J, Gao J. Clinical analysis of detection of markers related to infectious  
41 diseases. *Chin J of Nosocomiol* 2014; **24**(14): 3635-7.
- 42 47. Siransy LK, Nanga ZY, Zaba FS, Tufa NY, Dasse SR. ABO/Rh BLOOD GROUPS AND RISK OF  
43 HIV INFECTION AND HEPATITIS B AMONG BLOOD DONORS OF ABIDJAN, COTE D'IVOIRE.  
44 *Eur J Microbiol Immunol* 2015; **5**(3): 205-9.


- 1  
2 1 48. Navolan D, Vladareanu S, Ciohat I, et al. Prevalence of HBsAg Carrying Pregnant Women in  
3 2 Romania: Demographic and Behavioral Features. *Proceedings of the 49th Annual Scientific Meeting of*  
4 3 *the European Society for Clinical Investigation* 2015: 249-52.
- 5 4 49. Bisetegen FS, Bekele FB, Ageru TA, Wada FW. Transfusion-Transmissible Infections among  
6 5 Voluntary Blood Donors at Wolaita Sodo University Teaching Referral Hospital, South Ethiopia. *Can*  
7 6 *J Infect Dis Med Microbiol* 2016; (8254343).
- 8 7 50. Abate M, Wolde T. Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus,  
9 8 Hepatitis C Virus, and Syphilis among Blood Donors at Jigjiga Blood Bank, Eastern Ethiopia. *Ethiop J*  
10 9 *Health Sci* 2016; **26**(2): 155-62.
- 11 10 51. Bharadva S, Vachhani J, Dholakiya S. ABO and Rh association to transfusion transmitted  
12 11 infections among healthy blood donors in Jamnagar, Gujarat, India. *J Res Med Dent Sci* 2016; **4**(1): 58-  
13 12 62.
- 14 13 52. Naseri Z, Ghannad MS, Hosseini SM, Roshanaei G, Nejad ASM, Mohammadi A. Evaluation of  
15 14 Accompaniment of ABO Blood Groups System and Rhesus blood group types with Infection to  
16 15 Hepatitis B Virus and Hepatitis C Virus in Hamadan, Iran. *Int J of Med Res & Health Sci* 2016; **5**(4): 1-  
17 16 5.
- 18 17 53. Memon FA, Ujjan ID, Memon AI, Shaikh AR, Rao AR, Naz A. Seroprevalence of transfusion  
19 18 transmitted infections among different blood group donors at blood bank LUMHS, Hyderabad; *Pak*  
20 19 *J Med Sci* 2017; **33**(2):443-446.
- 21 20 54. Batool Z, Durrani SH, Tariq S. Association Of Abo And Rh Blood Group Types To Hepatitis B,  
22 21 Hepatitis C, Hiv And Syphilis Infection, A Five Year' Experience In Healthy Blood Donors In A  
23 22 Tertiary Care Hospital. *J Ayub Med Coll Abbottabad* 2017; **29**(1): 90-2.
- 24 23 55. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal  
25 24 six loci influencing plasma levels of liver enzymes. *Am J Hum Genet* 2008; **83**(4): 520-8.



**Figure 1.** The process of study selection for the meta-analysis.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

A




NOTE: Weights are from random effects analysis

B



NOTE: Weights are from random effects analysis



**Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**Additional file 1:****Table S1: The number of HBV-infected and uninfected subjects in each blood group.**

Author	A		B		AB		O	
	HBsAg+	HBsAg-	HBsAg+	HBsAg-	HBsAg+	HBsAg-	HBsAg+	HBsAg-
Terrier, E.1970 <sup>26</sup>	9	2452	4	605	2	255	40	2601
Leski, M.1970 <sup>27</sup>	16	53	4	10	0	5	14	53
Szmunness, W.1971 <sup>18</sup>	61	2893	25	1104	13	351	78	3571
Zuberi, S. J.1974 <sup>28</sup>	9	259	5	402	2	53	22	359
Vale, T. G.1974 <sup>29</sup>	18	303	6	140	5	104	11	249
Moore, H. H.1975 <sup>30</sup>	127	3519	103	3109	17	532	248	7261
Szmunness, W.1975 <sup>19</sup>	22	19530	5	6633	4	2468	27	22330
Lenka, M. R.1981 <sup>31</sup>	12	117	8	188	0	43	4	128
Nath, N.1985 <sup>32</sup>	22	524	9	260	3	69	34	664
Kulkarni, A. G.1986 <sup>33</sup>	51	338	17	530	18	78	79	749
Naidu, A. S.1986 <sup>34</sup>	49	195	42	297	11	51	43	341
Sebastian, V. J.1989 <sup>35</sup>	30	690	30	828	10	200	64	1424
Zhu, C.2002 <sup>36</sup>	44	2671	30	2158	18	678	61	3023
Joshi, S. K.2003 <sup>37</sup>	4	187	5	170	1	46	7	193
El-Gilany, A-H.2006 <sup>38</sup>	27	763	19	475	12	192	35	634
Behal, R.2008 <sup>20</sup>	106	4512	174	7252	38	1994	132	5792
Rifat-uz-Zaman2009 <sup>39</sup>	5	161	35	493	23	306	30	411
Dirisu, J. O.2011 <sup>40</sup>	32	38	39	36	1	2	128	151
Saeed Anwar, M.2011 <sup>41</sup>	103	3856	139	5871	17	627	208	5874
Omar, A. A. 2012 <sup>42</sup>	15	105	21	77	3	53	32	124
Tyagi, S.2013 <sup>43</sup>	27	1415	27	2096	9	445	32	1949
Sethi, B.2014 <sup>44</sup>	15	2480	10	2446	11	850	14	2058
Mohammadali, F.2014 <sup>17</sup>	2553	638825	1952	481845	627	153900	2707	745659
Nigam, J. S.2014 <sup>45</sup>	12	1011	11	1462	2	399	15	1216
Lao, T. T.2014 <sup>15</sup>	2038	18543	1991	18753	468	4670	3289	28953
Zhao, Y.2014 <sup>46</sup>	17	135	16	147	15	75	18	77
Siransy, L. K.2015 <sup>47</sup>	947	12299	941	12943	187	2575	2044	27578
Navolan, D.2015 <sup>48</sup>	15	606	7	218	4	109	7	419
Bisetegen, F. S.2016 <sup>49</sup>	7	97	10	67	2	7	18	182
Abate, M.2016 <sup>50</sup>	114	1901	54	936	9	202	470	3141
Bharadva, S.2016 <sup>51</sup>	62	9784	85	14548	22	3974	68	13366
Naseri, Z.2016 <sup>52</sup>	208	72275	180	53450	42	17213	210	84831
Memon, F. A.2017 <sup>53</sup>	15	1077	21	1350	9	297	21	1893
Liu, J.2017 <sup>16</sup>	64811	1103922	58286	1067812	18707	351184	73651	1088752
Batool, Z.2017 <sup>54</sup>	321	11468	289	12787	82	3771	277	12089

## Additional file 2:

Table S2-1: Agency for Healthcare Research and Quality table.

Author	1	2	3	4	5	6	7	8	9	10	11	Total
Terrier, E.1970 <sup>26</sup>	Y	N	N	U	U	Y	/	N	/	Y	Y	4
Leski, M.1970 <sup>27</sup>	Y	N	Y	N	U	Y	N	N	/	Y	Y	5
Szmunn, W.1971 <sup>18</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zuberi, S. J.1974 <sup>28</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Vale, T. G.1974 <sup>29</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Moore, H. H.1975 <sup>30</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Szmunn, W.1975 <sup>19</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Lenka, M. R.1981 <sup>31</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Nath, N.1985 <sup>32</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Kulkarni, A. G.1986 <sup>33</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Naidu, A. S.1986 <sup>34</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Sebastian, V. J.1989 <sup>35</sup>	Y	N	N	N	U	Y	/	N	N	Y	Y	4
Zhu, C.2002 <sup>36</sup>	Y	N	Y	Y	U	Y	N	N	N	N	Y	5
Joshi, S. K.2003 <sup>37</sup>	Y	Y	Y	N	U	Y	/	N	/	Y	Y	6
El-Gilany, A-H.2006 <sup>38</sup>	Y	Y	Y	N	U	Y	/	N	Y	N	Y	6
Behal, R.2008 <sup>20</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Rifat-uz-Zaman2009 <sup>39</sup>	Y	Y	Y	/	U	N	/	N	Y	Y	Y	6
Dirisu, J. O.2011 <sup>40</sup>	Y	Y	Y	Y	U	Y	/	N	/	Y	Y	7
Saeed Anwar, M.2011 <sup>41</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Omar, A. A. 2012 <sup>42</sup>	Y	N	Y	N	U	Y	/	N	/	Y	Y	5
Tyagi, S.2013 <sup>43</sup>	Y	Y	Y	N	U	Y	/	N	Y	Y	Y	7
Sethi, B.2014 <sup>44</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Mohammadali, F.2014 <sup>17</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Nigam, J. S.2014 <sup>45</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zhao, Y.2014 <sup>46</sup>	Y	N	Y	N	U	Y	/	N	Y	Y	Y	6
Siransy, L. K.2015 <sup>47</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Navolan, D.2015 <sup>48</sup>	Y	Y	N	N	U	Y	N	N	N	Y	Y	5
Bisetegen, F. S.2016 <sup>49</sup>	Y	Y	Y	N	U	Y	/	N	N	Y	Y	6
Abate, M.2016 <sup>50</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Bharadva, S.2016 <sup>51</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Naseri, Z.2016 <sup>52</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Memon, F. A.2017 <sup>53</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Liu, J.2017 <sup>16</sup>	Y	Y	Y	Y	U	Y	Y	Y	Y	Y	Y	9
Batool, Z.2017 <sup>54</sup>	Y	Y	Y	Y	U	Y	U	N	U	N	Y	6

Y, Yes; N, No; U, Unclear; /, not applicable.



**Table S2-2:** Newcastle-Ottawa Scales table.

Author	Year	Selection	Comparability	Outcome	Total
T. T. Lao 2014 <sup>15</sup>	2014	3	1	3	7

For peer review only



# PRISMA Checklist

Section/topic	#	Checklist item	Reported on page #
<b>TITLE</b>			
Title	1	Identify the report as a systematic review, meta-analysis, or both.	1
<b>ABSTRACT</b>			
Structured summary	2	Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number.	2
<b>INTRODUCTION</b>			
Rationale	3	Describe the rationale for the review in the context of what is already known.	3
Objectives	4	Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS).	4
<b>METHODS</b>			
Protocol and registration	5	Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number.	No
Eligibility criteria	6	Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale.	4
Information sources	7	Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched.	4
Search	8	Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated.	4
Study selection	9	State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis).	4
Data collection process	10	Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators.	4
Data items	11	List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made.	4-5
Risk of bias in individual studies	12	Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis.	5
Summary measures	13	State the principal summary measures (e.g., risk ratio, difference in means).	5
Synthesis of results	14	Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., $I^2$ ) for each meta-analysis.	5



# PRISMA Checklist

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47

Section/topic	#	Checklist item	Reported on page #
Risk of bias across studies	15	Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies).	5
Additional analyses	16	Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified.	5
<b>RESULTS</b>			
Study selection	17	Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram.	6
Study characteristics	18	For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations.	6-8
Risk of bias within studies	19	Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12).	8
Results of individual studies	20	For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot.	7
Synthesis of results	21	Present results of each meta-analysis done, including confidence intervals and measures of consistency.	8
Risk of bias across studies	22	Present results of any assessment of risk of bias across studies (see Item 15).	10
Additional analysis	23	Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]).	9-10
<b>DISCUSSION</b>			
Summary of evidence	24	Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers).	10
Limitations	25	Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias).	12
Conclusions	26	Provide a general interpretation of the results in the context of other evidence, and implications for future research.	12
<b>FUNDING</b>			
Funding	27	Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review.	13

# BMJ Open

## ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034114.R1
Article Type:	Original research
Date Submitted by the Author:	17-Dec-2019
Complete List of Authors:	Jing, wenzhan; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Zhao, Siyu; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Jue; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Min; Peking University, School of Public Health, Department of Epidemiology & Biostatistics
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Global health, Public health, Infectious diseases
Keywords:	Hepatitis B virus, ABO blood group, meta-analysis

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Title page**

2 **Title: ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis**

3 **Authors:** Wenzhan Jing, Siyu Zhao, Jue Liu \*, Min Liu \*

4 1 Wenzhan Jing, Department of Epidemiology and Biostatistics, School of Public Health, Peking

5 University; No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jingwenzhan@bjmu.edu.cn

6 2 Siyu Zhao, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

7 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: zhaosiyu@bjmu.edu.cn

8 3 Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

9 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jue Liu@bjmu.edu.cn

10 4 Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

11 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: liumin@bjmu.edu.cn

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

14 **Correspondence to:**

15 Prof. Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

16 Beijing 100191, China. (Tel: 86-10-82805146, Fax: 86-10-82805146, Email: liumin@bjmu.edu.cn);

17 Prof. Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

18 Beijing 100191, China. (Tel: 86-10-82801528, Fax: 86-10-82801528, Email: jue Liu@bjmu.edu.cn)

# 1 ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

## 2 Abstract

3 **Objective** Hepatitis B virus (HBV) infection is a major public health problem worldwide. Several studies  
4 have reported that ABO blood groups may be associated with HBV infection. However, its association is  
5 still controversial. We performed a meta-analysis to investigate whether ABO blood groups were  
6 associated with HBV infection.

7 **Design** Systematic review and meta-analysis.

8 **Data sources** Relevant studies available before December 1, 2019 were identified by searching PubMed,  
9 EMBASE, Web of Science, ScienceDirect, and the Cochrane Library.

10 **Eligibility criteria** All cross-sectional or cohort studies that the data of ABO blood group distribution and  
11 HBV infection could be extracted.

12 **Data extraction and synthesis** Studies were identified and extracted by two reviewers independently.  
13 Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled by random-effect models to quantify  
14 this association.

15 **Results** Thirty-eight eligible articles including 241,868 HBV-infected subjects and 6,487,481 uninfected  
16 subjects were included. Overall, the risk of HBV infection had decreased by 8% in subjects with blood  
17 group B when compared with blood group non-B (RR = 0.92, 95% CI: 0.86–0.98). In the subgroup  
18 analyses, the inverse relationship between blood group B and HBV infection remained stable in higher  
19 endemic areas (HBV prevalence  $\geq$  5%), Asian people, larger sample size studies ( $\geq$  2000), general  
20 population and blood donors, lower middle income group and studies published before 2010 years.  
21 Additionally, subjects with blood group O had a 12% increased risk of HBV infection (RR = 1.12, 95%  
22 CI:1.01-1.24) in higher endemic areas. In the sensitivity analysis, the pooled risk estimates of blood group  
23 B and HBV infection were still stable.

24 **Conclusions** Our data suggested that the blood group B was associated with a lower risk of HBV infection.  
25 More researches are needed to clarify the precise role of ABO blood group in HBV infection to address  
26 the global question of HBV infection.

## 27 Strengths and limitations of this study

28 ➤ The breadth of the comprehensive systematic literature search is a strength of this study.

1  
2 1 ➤ To our knowledge, this was the first meta-analysis of the association between ABO blood groups and  
3  
4 2 HBV infection.

5  
6  
7 3 ➤ Although we performed subgroup analyses, the heterogeneity cannot be ignored because few  
8  
9 4 published studies described the related risk factors of HBV infection in detail.

## 10 11 5 **Introduction**

12  
13  
14 6 Hepatitis B virus (HBV) infection is a major public health problem worldwide,<sup>1</sup> especially in Africa and  
15  
16 7 the Western Pacific Region.<sup>2</sup> According to the global hepatitis report in 2017, it is estimated that 257  
17  
18 8 million people, 3.5% of the general population, are living with HBV infection worldwide with about 0.88  
19  
20 9 million deaths caused by complications of chronic HBV infection every year.<sup>2</sup> HBV infection has caused  
21  
22 10 a high societal burden globally.<sup>1,2</sup>

23  
24  
25 11 The ABO blood group system, the most extensively investigated erythrocyte antigen system,<sup>3</sup> is widely  
26  
27 12 used in clinical practice, and influences the host susceptibility.<sup>4,5</sup> As an easily accessible factor in an  
28  
29 13 individual's genetic makeup, ABO blood groups have been not only statistically but also biologically  
30  
31 14 associated with many chronic diseases such as vascular disease,<sup>6</sup> coronary heart disease,<sup>7</sup> and  
32  
33 15 tumorigenesis.<sup>3,4,8</sup> For instance, by expressing on N-glycans of von Willebrand factor (VWF), ABH  
34  
35 16 antigens (H antigen is the biosynthetic precursor to A and B antigens<sup>5</sup>) impact the half-life of VWF, so  
36  
37 17 VWF survival in O subjects is significantly shorter versus (vs.) in non-O subjects.<sup>9-11</sup> Therefore, because  
38  
39 18 of the lower VWF levels, O subjects have lower risk of venous thromboembolism.<sup>10</sup> Recently, a meta-  
40  
41 19 analysis also found that hepatocellular carcinoma (HCC) patients might have a lower proportion of O  
42  
43 20 subjects than healthy subjects.<sup>12</sup> Meanwhile, the association between ABO blood groups and host  
44  
45 21 susceptibility to infectious diseases (such as helicobacter pylori, plasmodium falciparum, and human  
46  
47 22 immunodeficiency virus, etc.) has been shown in several studies.<sup>5,13</sup> Previous studies have found the  
48  
49 23 reasons for this association were that ABO antibodies are part of the innate immune system against some  
50  
51 24 bacteria, parasites and enveloped viruses,<sup>5</sup> and blood antigens are important as receptors for immune and  
52  
53 25 inflammation response,<sup>14,15</sup> which means the biologic association between ABO blood groups and HBV  
54  
55 26 infection probably exist.

56  
57 27 Epidemiologic studies have explored the relationship between blood group and HBV infection, however,  
58  
59 28 the results have been contradictory. Lao et al.<sup>16</sup> found that HBV prevalence was lower in blood group B  
60



(9.6%) and AB (9.1%), but higher in blood group O (10.2%). Liu et al.<sup>17</sup> suggested that blood group O was associated with increased HBV infection. Mohammadali et al.<sup>18</sup> found that the percentage of hepatitis B surface antigen (HBsAg) was lower in donors who had blood group O. However, Szmuness et al.<sup>19,20</sup> and Behal et al.<sup>21</sup> failed to find a link between blood group and HBV infection. Thus, controversy remains with regard to whether blood group is related to HBV infection and which antigen is a protective or a risk factor. We performed a systematic review and meta-analysis to elucidate the association between ABO blood groups and HBV infection risk to provide evidence on improving blood safety and preventing HBV infection, which can help to achieve the target of eliminating HBV as an international public health challenge.<sup>22</sup>

## **Materials and methods**

### **Data sources and search strategy**

Two reviewers (SZ and WJ) searched independently for articles, which were available online before December 1, 2019, from five databases including PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central using the following keywords: “hepatitis B” OR “hepatitis B virus” OR “HBV” OR “HBsAg” and “blood type” OR “blood group” OR “ABO” OR “Rh” OR “rhesus”. Meanwhile, highly relevant reference articles were also searched by reviewing the list of references. There was no limitation of language or region. The full electronic search strategy for PubMed are shown in Additional file 1.

### **Inclusion and exclusion criteria**

Articles were included in the meta-analysis if: (1) the article was a cross-sectional or cohort study; (2) the data of the ABO blood group distribution and HBV infection could be extracted to calculate the risk ratio (RR), which meant that the number of HBV-infected and uninfected subjects were reported in each blood group. The exclusion criteria were as follows: (1) the article was not relevant to the subject of the study (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies, where if studies overlapped, we only included the last published; and (4) duplicated studies, where if the same study was found in different databases, we only included the article once.

According to the inclusion and exclusion criteria, studies were identified by two reviewers (SZ and WJ) independently. Discrepancies were solved by consensus or decided by a third reviewer (JL).

## 1 **Data extraction and quality assessment**

2 According to the piloted forms, four main parts of the information were extracted independently by two  
3 reviewers (SZ and WJ) from the selected studies: (1) the basic information of the studies including first  
4 author, publication year, journal, survey time, study design; (2) the characteristics of the study population  
5 including country, income group, race, population type (e.g., blood donors, patients, general population),  
6 sample size, the number of HBV-infected and uninfected subjects, age range, mean age, sex ratio; (3) the  
7 outcome measure: the number of HBV-infected and uninfected subjects in each ABO blood group; and  
8 (4) the author's general conclusions.

9 The quality of selected cohort studies were assessed using the Newcastle-Ottawa Scales (NOS) with a  
10 score ranging from 0 to 9.<sup>23</sup> A score of 4–6 indicated moderate quality, and a score of 7–9 indicated high  
11 quality. The quality of the selected cross-sectional studies were assessed using an 11-item checklist  
12 recommended by the Agency for Healthcare Research and Quality (AHRQ)<sup>24</sup> with a score ranging from 0  
13 to 11. A score of 4–7 indicated moderate quality, and a score of 8–11 indicated high quality.

## 14 **Statistical analysis**

15 The main outcome was the prevalence of HBV infection (defining as HBsAg-positive) in our meta-  
16 analysis. The relationship between the ABO blood groups and HBV infection was quantified using RR  
17 values and the corresponding 95% confidence intervals (CIs). RRs and 95% CIs (A vs. non-A, B vs. non-B,  
18 O vs. non-O, AB vs. non-AB) were pooled by using of random-effect models with the estimate of  
19 heterogeneity being taken from the Mantel-Haenszel model, and  $P < 0.05$  was deemed significantly.  
20 Meanwhile,  $I^2$  was used to evaluate heterogeneity among the studies. When  $I^2 \leq 50\%$ , the included studies  
21 were considered to have little heterogeneity; when  $I^2 > 50\%$ , the included studies were considered to have  
22 substantial heterogeneity.<sup>25</sup>

23 Subgroup analyses were performed by HBV prevalence, race, sample size, population, income group,  
24 study type, and publication year. The prevalence of HBV infection was calculated in each study based on  
25 the number of HBV-infected and uninfected subjects. Studies were divided into Caucasian, Asian, and  
26 African subgroups depending on the major national race and divided into high, upper middle, lower middle  
27 and low income groups according to the World Bank list of economies.<sup>26</sup> Sensitivity analyses were  
28 performed by excluding large sample size studies orderly or at the same time, which dominated the results

1 of the meta-analysis. Publication bias was evaluated by funnel plots and two-sided Egger's tests, and  $P <$   
2 0.05 was deemed significantly. All statistical analyses were performed with STATA version 12.0.

### 3 **Patient and public involvement**

4 There was no direct patient or public involvement in this review.

## 5 **Results**

### 6 **Study selection and study characteristics**

7 A total of 4486 articles (4476 from database and 10 from other sources) were searched, of which 1584  
8 were duplicate results. After reading the abstracts, 2211 were deemed irrelevant and three reviews were  
9 excluded. After reading the full text, 650 articles were excluded, of which 610 were irrelevant articles, and  
10 40 studies provided insufficient information. Eventually, 38 eligible articles were included in the meta-  
11 analysis. A flow-chart of study selection was shown as Figure 1.

12  
13 **Insert Figure 1.** The process of study selection for the meta-analysis.

14  
15 The basic characteristics of the selected studies are shown in Table 1. All selected articles were  
16 observational studies and published between 1970 and 2019. A total of 6,487,481 subjects were included  
17 with 241,868 HBV-infected subjects and 6,245,613 uninfected subjects. Among the Caucasian, Asian, and  
18 African population, there were 23, 7, and 8 studies, respectively. In addition, there were 7, 9, 18 and 4  
19 study in high income, upper middle income, lower middle income and low income group, respectively.  
20 Furthermore, there were 14 studies in higher (HBV prevalence  $\geq 5\%$ ) endemic and 24 studies in lower  
21 (HBV prevalence  $< 5\%$ ) endemic areas, respectively. Meanwhile, there were 37 cross-sectional studies and  
22 1 cohort study in the meta-analysis.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**Table 1.** Characteristics of the included studies.

Author	Income group	Race	Population	Sample size	HBV infection (n/%)				
					Total	A, non-A <sup>a</sup>	B, non-B <sup>a</sup>	AB, non-AB <sup>a</sup>	O, non-O <sup>a</sup>
Terrier, E.1970 <sup>27</sup>	High	Caucasian	Blood donors	5968	55/0.92	9/0.37, 46/1.31	4/0.66, 51/0.95	2/0.78, 53/0.93	40/1.51, 15/0.45
Leski, M.1970 <sup>28</sup>	High	Caucasian	Patients	155	34/21.94	16/23.19, 18/20.93	4/28.57, 30/21.28	0/0, 34/22.67	14/20.9, 20/22.73
Szmunn, W.1971 <sup>19</sup>	High	Caucasian	Blood donors	8096	177/2.19	61/2.06, 116/2.26	25/2.21, 152/2.18	13/3.57, 164/2.12	78/2.14, 99/2.23
Zuberi, S. J.1974 <sup>29</sup>	Lower middle	Caucasian	Blood donors	1111	38/3.42	9/3.36, 29/3.44	5/1.23, 33/4.69	2/3.64, 36/3.41	22/5.77, 16/2.19
Vale, T. G.1974 <sup>30</sup>	Lower middle	African	General	836	40/4.78	18/5.61, 22/4.27	6/4.11, 34/4.93	5/4.59, 35/4.81	11/4.23, 29/5.03
Moore, H. H.1975 <sup>31</sup>	Low	Caucasian	Blood donors	14916	495/3.32	127/3.48, 368/3.27	103/3.21, 392/3.35	17/3.1, 478/3.33	248/3.3, 247/3.33
Szmunn, W.1975 <sup>20</sup>	High	Caucasian	Blood donors	51019	58/0.11	22/0.11, 36/0.11	5/0.08, 53/0.12	4/0.16, 54/0.11	27/0.12, 31/0.11
Lenka, M. R.1981 <sup>32</sup>	Lower middle	Caucasian	Blood donors	500	24/4.8	12/9.3, 12/3.23	8/4.08, 16/5.26	0/0, 24/5.25	4/3.03, 20/5.43
Nath, N.1985 <sup>33</sup>	Lower middle	Caucasian	Blood donors	1585	68/4.29	22/4.03, 46/4.44	9/3.35, 59/4.48	3/4.17, 65/4.30	34/4.87, 34/3.83
Kulkarni, A. G.1986 <sup>34</sup>	Lower middle	African	Blood donors	1860	165/8.87	51/13.11, 114/7.85	17/3.11, 148/11.27	18/18.75, 147/8.33	79/9.54, 86/8.33
Naidu, A. S.1986 <sup>35</sup>	High	Caucasian	Blood donors	1029	145/14.09	49/20.08, 96/12.40	42/12.39, 103/14.93	11/17.74, 134/13.86	43/11.20, 102/15.81
Sebastian, V. J.1989 <sup>36</sup>	Upper middle	Asian	Blood donors	3276	134/4.09	30/4.17, 104/4.08	30/3.50, 104/4.30	10/4.76, 124/4.04	64/4.30, 70/3.91
Zhu, C.2002 <sup>37</sup>	Low	Asian	Blood donors	8683	153/1.76	44/1.62, 109/1.83	30/1.37, 123/1.89	18/2.59, 135/1.69	61/1.98, 92/1.64
Joshi, S. K.2003 <sup>38</sup>	Lower middle	Asian	General	613	17/2.77	4/2.09, 13/3.08	5/2.86, 12/2.74	1/2.13, 16/2.83	7/3.5, 10/2.42
El-Gilany, A-H.2006 <sup>39</sup>	Lower middle	Caucasian	Blood donors	2157	93/4.31	27/3.42, 66/4.87	19/3.85, 74/4.45	12/5.88, 81/4.15	35/5.23, 58/3.90
Behal, R.2008 <sup>21</sup>	Lower middle	Caucasian	Blood donors	20000	450/2.25	106/2.30, 344/2.24	174/2.34, 276/2.20	38/1.87, 412/2.29	132/2.23, 318/2.26
Rifat-uz-Zaman2009 <sup>40</sup>	Lower middle	Caucasian	General	1464	93/6.35	5/3.01, 88/6.90	35/6.63, 58/6.20	23/6.99, 70/6.17	30/6.80, 63/6.16
Dirisu, J. O.2011 <sup>41</sup>	Lower middle	African	Blood donors	427	200/46.84	32/45.71, 168/47.06	39/52, 161/45.74	1/33.33, 199/46.93	128/45.88, 72/48.65
Saeed Anwar, M.2011 <sup>42</sup>	Upper middle	Caucasian	Blood donors	16695	467/2.80	103/2.60, 364/2.86	139/2.31, 328/3.07	17/2.64, 450/2.80	208/3.42, 259/2.44
Omar, A. A. 2012 <sup>43</sup>	Lower middle	Caucasian	Blood donors	430	71/16.51	15/12.5, 56/18.06	21/21.43, 50/15.06	3/5.36, 68/18.18	32/20.51, 39/14.23
Tyagi, S.2013 <sup>44</sup>	Lower middle	Caucasian	Blood donors	6000	95/1.58	27/1.87, 68/1.49	27/1.27, 68/1.75	9/1.98, 86/1.55	32/1.62, 63/1.57
Sethi, B.2014 <sup>45</sup>	Upper middle	Caucasian	Blood donors	7884	50/0.63	15/0.60, 35/0.65	10/0.41, 40/0.74	11/1.28, 39/0.56	14/0.68, 36/0.62
Mohammadali, F.2014 <sup>18</sup>	Lower middle	Caucasian	Blood donors	2028068	7839/0.39	2553/0.40, 5286/0.38	1952/0.40, 5887/0.38	627/0.41, 7212/0.38	2707/0.36, 5132/0.40
Nigam, J. S.2014 <sup>46</sup>	High	Caucasian	Blood donors	4128	40/0.97	12/1.17, 28/0.90	11/0.75, 29/1.09	2/0.50, 38/1.02	15/1.22, 25/0.86
Lao, T. T.2014 <sup>16 b</sup>	Upper middle	Asian	General	78705	7786/9.89	2038/9.90, 5748/9.97	1991/9.60, 5795/10.00	468/9.11, 7318/9.95	3289/10.20, 4497/9.68
Zhao, Y.2014 <sup>47</sup>	Lower middle	Asian	Patients	500	66/13.20	17/11.18, 49/14.71	16/9.82, 50/14.84	15/16.67, 51/12.44	18/18.95, 48/11.85
Siransy, L. K.2015 <sup>48</sup>	Lower middle	African	Blood donors	59514	4119/6.92	947/7.15, 3172/6.86	941/6.78, 3178/6.96	187/6.77, 3932/6.93	2044/6.9, 2075/6.94
Navolan, D.2015 <sup>49</sup>	Upper middle	Caucasian	General	1385	33/2.38	15/2.42, 18/2.37	7/3.11, 26/2.24	4/3.54, 29/2.28	7/1.64, 26/2.71
Bisetegen, F. S.2016 <sup>50</sup>	Lower middle	African	Blood donors	390	37/9.49	7/6.73, 30/10.49	10/12.99, 27/8.63	2/22.22, 35/9.19	18/9, 19/10
Abate, M.2016 <sup>51</sup>	Upper middle	African	Blood donors	6827	647/9.48	114/5.66, 533/11.10	54/5.45, 593/10.16	9/4.27, 638/9.64	470/13.02, 177/5.50
Bharadva, S.2016 <sup>52</sup>	Lower middle	Caucasian	Blood donors	41909	237/0.57	62/0.63, 175/0.55	85/0.58, 152/0.56	22/0.55, 215/0.57	68/0.51, 169/0.59
Naseri, Z.2016 <sup>53</sup>	High	Caucasian	Blood donors	228409	640/0.28	208/0.29, 432/0.28	180/0.34, 460/0.26	42/0.24, 598/0.28	210/0.25, 430/0.30
Memon, F. A.2017 <sup>54</sup>	Lower middle	Caucasian	Blood donors	4683	66/1.41	15/1.37, 51/1.42	21/1.53, 45/1.36	9/2.94, 57/1.30	21/1.10, 45/1.63
Liu, J.2017 <sup>17</sup>	Lower middle	Asian	General	3827125	215455/5.63	64811/5.55, 150644/5.71	58286/5.18, 157169/5.82	18707/5.06, 196748/5.69	73651/6.34, 141804/5.32
Batool, Z.2017 <sup>55</sup>	Low	Caucasian	Blood donors	41084	969/2.36	321/2.72, 648/2.22	289/2.21, 680/2.43	82/2.13, 887/2.38	277/2.24, 692/2.41
Ngassaki-Y, C-D.2018 <sup>56</sup>	Upper middle	African	Blood donors	4744	81/1.71	-	-	-	34/1.22, 47/2.41
Fu, X.2018 <sup>57</sup>	Upper middle	Asian	Patients	2000	389/19.45	105/21.43, 284/18.81	89/18.94, 300/19.61	59/21.85, 330/19.08	136/17.66, 253/20.57
Nkansah, C.2019 <sup>58</sup>	Lower middle	African	Blood donors	3306	342/10.34	48/11.76, 294/10.21	63/9.35, 279/10.67	1/3.33, 341/10.47	230/10.48, 112/10.07

<sup>a</sup> The number of HBV infected people in the X blood group/HBV prevalence (%) in the X blood group; the number of HBV infected people in the non-X blood group/HBV prevalence (%) in the non-X blood group. <sup>b</sup> A cohort study.

1 The HBV infection prevalence in the 38 eligible articles ranged from 0.11% to 46.84%, and the HBV  
2 infection prevalence of blood group A, B, AB, O ranged from 0.11% to 45.71%, 0.08% to 52.00%, 0.00%  
3 to 33.33%, and 0.12% to 45.88%, respectively. The results of the quality assessment are shown in  
4 Additional file 2, with 15 high quality studies and 23 moderate quality studies. The score of the 37 articles  
5 assessed by AHRQ ranged from 3 to 9, while 14 of them were of high-quality with a score from 8 to 9,  
6 and 23 of them were of moderate-quality with a score from 4 to 7. The article assessed by NOS scored 7  
7 and was of high-quality.

### 8 **Main, subgroup, and sensitivity analyses**

9 Overall, the risk of HBV infection had decreased by 8% in subjects with blood group B when compared  
10 with blood group non-B (RR = 0.92, 95% CI: 0.86–0.98). However, blood groups A, O and AB were not  
11 significantly associated with an HBV infection risk (Table 2). The results of the subgroup analyses are  
12 shown in Table 2. In the subgroup analyses, the relationship between blood group B and HBV infection  
13 remained stable. The inverse relationship between blood group B and HBV infection was still observed in  
14 the higher endemic areas (HBV prevalence  $\geq$  5%), Asian people, studies with larger sample sizes ( $\geq$   
15 2000), general population and blood donors, lower middle income group, and articles published before  
16 2010 years (Table 2).

1  
2  
3  
4 **Table 2.** The main, subgroup and sensitivity analyses.

Subgroup	No. of studies	Sample size	B vs. Non-B		O vs. Non-O		A vs. Non-A		AB vs. Non-AB	
			RR (95% CI)	P value	RR (95% CI)	P value	RR (95% CI)	P value	RR (95% CI)	P value
All studies	38	6487481	0.92 (0.86,0.98)	0.007	1.07 (1.01,1.15)	0.082	1.01 (0.96, 1.07)	0.728	1.04 (0.95,1.13)	0.419
HBV prevalence										
Higher endemic (≥5%)	14	3983732	0.90 (0.83,0.98)	0.013	1.12 (1.01,1.24)	0.025	0.99 (0.91,1.08)	0.820	1.00 (0.89,1.14)	0.962
Lower endemic (<5%)	24	2503749	0.93 (0.85,1.02)	0.126	1.03 (0.93,1.15)	0.566	1.03 (0.95,1.11)	0.471	1.06 (0.95,1.18)	0.292
Race										
Caucasian	23	2488675	0.96 (0.87, 1.05)	0.386	1.04 (0.94, 1.16)	0.465	1.03 (0.94, 1.13)	0.472	1.05 (0.93, 1.18)	0.461
Asian	7	3920902	0.91(0.86, 0.97)	0.003	1.10 (0.99, 1.22)	0.075	0.98 (0.97, 0.99)	<0.001	0.96 (0.87, 1.06)	0.451
African	8	77904	0.78 (0.58, 1.05)	0.099	1.04 (0.77, 1.40)	0.803	0.99 (0.73, 1.33)	0.919	1.02 (0.62, 1.67)	0.953
Sample size										
≥2000	24	6475196	0.93 (0.87, 0.99)	0.018	1.07 (0.98, 1.16)	0.135	0.99 (0.94, 1.05)	0.795	1.00 (0.92, 1.08)	0.914
<2000	14	12285	0.85 (0.64, 1.13)	0.275	1.08 (0.90, 1.29)	0.398	1.07 (0.85, 1.33)	0.577	1.20 (0.89, 1.61)	0.238
Population										
General	6	3910128	0.93 (0.87, 0.99)	0.016	1.07 (0.99, 1.15)	0.078	0.98 (0.96, 1.00)	0.035	0.89 (0.88, 0.90)	<0.001
Blood donors	29	2574698	0.89 (0.81, 0.97)	0.011	1.08 (0.97, 1.20)	0.154	1.01 (0.92, 1.10)	0.885	1.08 (0.95, 1.23)	0.248
Patients	3	2655	0.92 (0.71, 1.19)	0.517	1.04 (0.71, 1.54)	0.828	1.09 (0.91, 1.30)	0.345	1.17 (0.94, 1.46)	0.169
Income group										
High	7	148804	0.96 (0.91,1.00)	0.065	1.17 (0.95,1.44)	0.135	0.91 (0.74,1.11)	0.343	0.97 (0.84,1.13)	0.712
Upper middle	9	6101344	1.01 (0.88,1.15)	0.927	0.97 (0.82, 1.15)	0.756	1.00 (0.96,1.06)	0.791	1.02 (0.88,1.17)	0.814
Lower middle	18	214587	0.86 (0.76,0.97)	0.011	1.03 (0.93,1.13)	0.582	1.13(1.01,1.25)	0.030	1.13 (0.95,1.34)	0.173
Low	4	22746	0.88 (0.56,1.38)	0.572	1.34 (0.72, 2.48)	0.353	0.71 (0.42,1.21)	0.209	0.84 (0.43,1.64)	0.613
Study design										
Cross-sectional	37	6408776	0.91 (0.85, 0.97)	0.007	1.07 (0.98, 1.17)	0.111	1.01 (0.95,1.08)	0.780	1.06 (0.96, 1.17)	0.244
Cohort	1	78705	0.96 (0.92, 1.01)	0.098	1.05 (1.01, 1.10)	0.016	1.00 (0.95, 1.05)	0.957	0.92 (0.84, 1.00)	0.053
Publication year										
Before 2010	17	123268	0.80 (0.67, 0.96)	0.015	1.12 (0.97, 1.29)	0.112	1.02 (0.85, 1.22)	0.830	1.22 (1.01, 1.46)	0.040
After 2010	21	6364213	0.95 (0.88, 1.01)	0.106	1.05 (0.95, 1.15)	0.335	1.00 (0.94, 1.06)	0.910	0.98 (0.89, 1.07)	0.627
Sensitive analyses										
Removed Liu's study <sup>17</sup>	37	2660356	0.91 (0.85, 0.98)	0.012	1.06 (0.98, 1.15)	0.138	1.01 (0.94, 1.08)	0.816	1.06 (0.97, 1.17)	0.213
Removed Mohammedali's study <sup>18</sup>	37	4459413	0.91 (0.85, 0.97)	0.002	1.08 (1.00, 1.16)	0.044	1.01 (0.94, 1.07)	0.857	1.04 (0.95, 1.14)	0.445
Removed both Liu's and Mohammedali's study <sup>17,18</sup>	36	632288	0.90 (0.83, 0.97)	0.007	1.07 (0.98, 1.17)	0.115	1.00 (0.92, 1.09)	0.946	1.08 (0.96, 1.20)	0.211

3 RR: Risk ratio.

4  
5 In higher endemic areas, subjects with blood group B had a significantly lower risk of HBV infection  
6 (RR = 0.90, 95% CI: 0.83–0.98) than the non-B group (Figure 2A), while subjects with the blood group  
7 O had a significantly higher risk of HBV infection (RR = 1.12, 95% CI: 1.01–1.24) than the non-O group  
8 (Figure 2B). According to the race of the subjects, blood group A and B were linked with decreased risk  
9 of HBV infection in the Asian population when compared to non-A and non-B, respectively (OR = 0.98,  
10 95%CI: 0.97–0.99; OR = 0.91, 95% CI: 0.86–0.97) (Table 2). However, no association was found among

1 the Caucasian or African population. In general population, blood group A, B and AB had a decreased risk  
2 of HBV infection compared to non-A, non-B and non-AB, respectively (OR = 0.98, 95%CI: 0.96–1.00;  
3 OR = 0.93, 95% CI: 0.87–0.99 and OR = 0.89, 95% CI: 0.88–0.90, respectively) (Table 2).

4  
5 **Insert Figure 2.** Forest plots by prevalence: (A) B vs. non-B; (B) O vs. non-O.

6  
7 In the sensitivity analysis, when the study of Liu et al.<sup>17</sup> and Mohammadali et al.<sup>18</sup>, which dominated  
8 the results of the meta-analysis, were orderly removed or both removed at the same time, the pooled risk  
9 estimates were still stable, showing that blood B was associated with a lower risk of HBV infection (Table  
10 2).

### 11 **Publication bias**

12 Funnel plots and Egger's tests were performed to assess publication bias. No obvious evidence of  
13 publication bias was present for A vs. non-A, B vs. non-B, and O vs. non-O ( $P = 0.148$ ;  $P = 0.223$ ;  $P =$   
14  $0.364$ , respectively), while a publication bias of AB vs. non-AB was observed ( $P = 0.002$ ) (Figure 3).

15 **Insert Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

### 17 **Discussion**

18 To our knowledge, this was the first meta-analysis of the association between ABO blood groups and HBV  
19 infection. Our meta-analysis results suggested that blood group B was associated with a lower risk of HBV  
20 infection, which was observed in subgroups and still stable in sensitive analyses, giving supportive  
21 evidence that not only statistical association but also biologic association between ABO blood groups and  
22 HBV infection probably exists.

23 As an infectious disease, aside from genetic susceptibility factors, there is the question of whether  
24 exposure to the source of infection is directly related to the risk of infection. People living in higher  
25 endemic areas are at higher risk of exposure to HBV than those living in lower endemic areas, which might  
26 be the reason why the association between ABO blood group and HBV infection was only found in higher  
27 endemic areas but not in lower endemic areas. Additionally, this association might be partly attributed to the  
28 regional factors, due to the high relevance between HBV endemic and region.

1 The implementation of universal hepatitis B vaccination program for newborns was started in 1992  
2 proposed by WHO. All the selected articles were published between 1970 and 2019, which meant that  
3 even in the same country, the prevalence of HBV infection has changed significantly due to increasing  
4 coverage of hepatitis B vaccination. However, no enough information could be extracted from the previous  
5 studies to compare the pooled association of ABO blood group and HBV infection between vaccinated  
6 group and unvaccinated group. To partially examine the impact of hepatitis B vaccination on the results,  
7 we did subgroup analyses according to publication year before and after 2010. Subjects in the selected  
8 articles were mainly people over 18 years old. Thus, subjects in articles published after 2010 were more  
9 likely to be vaccinated at the time of birth, while subjects were mostly not vaccinated at birth in the articles  
10 published before 2010. We observed the association of blood group B and HBV infection in the articles  
11 published before 2010 rather than after 2010. The gradual establishment of an HBV immune barrier in the  
12 population may affect the occurrence of the relationship between ABO blood type and HBV infection.

13 Our results found that subjects with blood group O were at higher risk of HBV infection in higher  
14 endemic areas, which was consistent with some previous studies of Lao et al.<sup>16</sup>, Liu et al.<sup>17</sup> and Abate et  
15 al.<sup>51</sup> That means more measures should be taken to ensure the “universal” group-O blood safety in high  
16 endemic areas because of the large unvaccinated population among the main blood donors in current era  
17 and the window period for detection among the HBV-infected blood donors.<sup>17</sup> However, this relationship  
18 was unobserved in other subgroup analysis, so whether this relationship was true remains to be further  
19 explored. Interestingly, our result that blood group B was associated with a lower risk of HBV infection  
20 compared with blood group non-B was few reported explicitly by other studies, possibly because of the  
21 different analysis methods, such as the different reference of blood group in analysis.

22 However, the study of Mohammadali et al.<sup>18</sup>, with the second largest sample size, reported that HBV  
23 infection was lower in group-O donors, opposing to the study with the largest sample by Liu et al.,<sup>17</sup>  
24 probably due to the different HBV prevalence, geography and ethnicity. Our meta-analysis was  
25 inconsistent with the recently meta-analysis, which found that HCC patients might have a lower proportion  
26 of O subjects than healthy subjects.<sup>12</sup> The possible explanation for the inconsistency is the long-term and  
27 complicated process from HBV infection to the occurrence of HCC. To examine the reliable and stable of  
28 the results, we orderly removed the study of Liu et al.<sup>17</sup> or Mohammadali et al.<sup>18</sup>, as well as removed both  
29 of them at the same time. In the sensitive analysis, the relationship between blood group O and HBV  
30 infection may be unstable. However, the inverse relationship between blood group B and HBV infection



1 was extremely stable. Therefore, we still thought that these findings were worthy of consideration due to  
2 the subgroup analyses, the sensitive analyses and the relatively conservative random effects model.

3 Although the precise role that ABO blood groups play in host susceptibility and HBV infection has yet  
4 to be clarified,<sup>17</sup> associations have been observed most likely related to the altered immune response<sup>16</sup> and  
5 systemic inflammatory response<sup>15</sup> associated with different blood group phenotypes. A previous study has  
6 reported that the appearance of intestinal alkaline phosphatase in the plasma was associated with the ABO  
7 blood group and secretor status, which may be due to genetically determined variations in the proportion  
8 of isoenzymes among the different blood types<sup>59</sup>. Our study may indicate that specific histo-bloodgroup  
9 antigen may be a natural resistance factor for HBV infection, and that probably provides clues for  
10 correlative fundamental researches of etiologies and novel therapeutic targets for HBV. Further studies  
11 are warranted to elucidate the association between blood group and HBV infection, and the way the blood  
12 type influences the process of HBV infection.

13 Meanwhile, several limitations need to be considered. First, although we performed subgroup analyses,  
14 analyses of previous studies have revealed that the heterogeneity cannot be ignored. Second, the analyzed  
15 studies lacked the basic information of the ethnicity data and the prevalence of different HBV genotypes.  
16 Third, few published studies on the association between HBV infection and blood group have controlled  
17 HBV infection related risk factors such as family history of HBV infection, age group, blood transfusion,  
18 and acupuncture, thus we were not able to conduct the corresponding subgroup analyses.

19 In conclusion, blood group B was associated with a lower risk of HBV infection. In the future, more  
20 researches are needed to clarify the precise role of the ABO blood group in HBV infection to address the  
21 global question of HBV infection.

## 22 **Supplementary**

23 Additional file 1: The electronic search strategy for PubMed.

24 Additional file 2: Quality assessment tables.

25  
26  
27 **Abbreviations** HBV, Hepatitis B virus; OR, odds ratio; CI, confidence interval; VTE, venous  
28 thromboembolism; vs., versus; VWF, von Willebrand factor; HBsAg, hepatitis B surface antigen; Rh,

1 rhesus; RR, risk ratio; NOS, Newcastle-Ottawa Scales; AHRQ, Agency for Healthcare Research and  
2 Quality.

3  
4 **Contributions** All authors contributed to this work. ML and JL conceived and designed the study strategy;  
5 SZ and WJ independently completed the processes of the article search, article assessment, data extraction,  
6 quality assessment, and data analysis; and WJ wrote the manuscript. All authors read and approved the final  
7 manuscript.

8 **Funding** This study was supported by the National Natural Science Foundation of China (Grant No. 71934002,  
9 No. 71874003 and No. 81703240).

10 **Competing interests** The authors declare that they have no competing interests.

11 **Patient consent for publication** Not required.

12 **Provenance and peer review** Not commissioned; externally peer reviewed.

13 **Availability of data and material** All data generated or analyzed during this study are included in this  
14 published article and its supplementary information files.

15 **Open access** This is an open access article distributed in accordance with the Creative Commons Attribution  
16 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon  
17 this work for any purpose, provided the original work is properly cited, a link to the licence is given, and  
18 indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.


## 20 REFERENCES

- 21 1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. *Lancet* 2014; **384**(9959): 2053-63.
- 22 2. WHO. Global hepatitis report, 2017. 2017. <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/#>.
- 23 3. Li B, Tan B, Chen C, Zhao L, Qin L. Association between the ABO blood group and risk of common  
24 cancers. *J Evid Based Med* 2014; **7**(2): 79-83.
- 25 4. Wang W, Liu L, Wang Z, et al. ABO blood group and esophageal carcinoma risk: from a case-control  
26 study in Chinese population to meta-analysis. *Cancer Causes Control* 2014; **25**(10): 1369-77.
- 27 5. Cooling L. Blood Groups in Infection and Host Susceptibility. *Clin Microbiol Rev* 2015; **28**(3): 801-70.
- 28 6. Alpoim PN, de Barros Pinheiro M, Junqueira DR, et al. Preeclampsia and ABO blood groups: a systematic  
29 review and meta-analysis. *Mol Biol Rep* 2013; **40**(3): 2253-61.
- 30 7. He M, Wolpin B, Rexrode K, et al. ABO blood group and risk of coronary heart disease in two prospective  
31 cohort studies. *Arterioscler Thromb Vasc Biol* 2012; **32**(9): 2314-20.
- 32 8. Miao SY, Zhou W, Chen L, Wang S, Liu XA. Influence of ABO blood group and Rhesus factor on breast  
33 cancer risk: a meta-analysis of 9665 breast cancer patients and 244,768 controls. *Asia Pac J Clin Oncol* 2014;  
34

- 1  
2 1 10(2): 101-8.
- 3 2 9. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic  
4 3 function after all? *Transfusion* 2006; **46**(10): 1836-44.
- 5 4 10. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group  
6 5 subjects explains how ABO determinants influence plasma von Willebrand factor. *Blood* 2008; **111**(7): 3540-  
7 6 5.
- 8 7 11. Anstee DJ. The relationship between blood groups and disease. *Blood* 2010; **115**(23): 4635-43.
- 9 8 12. Liu F, Li C, Zhu J, Ren L, Qi X. ABO blood type and risk of hepatocellular carcinoma: a meta-analysis.  
10 9 *Expert Rev Gastroenterol Hepatol* 2018; **12**(9): 927-33.
- 11 10 13. Branch DR. Blood groups and susceptibility to virus infection: new developments. *Curr Opin Hematol*  
12 11 2010; **17**(6): 558-64.
- 13 12 14. Pare G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble  
14 13 ICAM-1: results of a genome-wide association study of 6,578 women. *PLoS Genet* 2008; **4**(7): e1000118.
- 15 14 15. Zhou Y, Zhou Q, Lin Q, et al. Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood  
16 15 group, hepatitis B virus and their synergism. *Int J Cancer* 2013; **133**(8): 1867-75.
- 17 16 16. Lao TT, Sahota DS, Chung MK, Cheung TK, Cheng YK, Leung TY. Maternal ABO and rhesus blood  
18 17 group phenotypes and hepatitis B surface antigen carriage. *J Viral Hepat* 2014; **21**(11): 818-23.
- 19 18 17. Liu J, Zhang S, Liu M, Wang Q, Shen H, Zhang Y. Distribution of ABO/Rh blood groups and their  
20 19 association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based cross-sectional  
21 20 study. *J Viral Hepat* 2018; **25**(4): 401-11.
- 22 21 18. Mohammadali F, Pourfathollah A. Association of ABO and Rh Blood Groups to Blood-Borne Infections  
23 22 among Blood Donors in Tehran-Iran. *Iran J Public Health* 2014; **43**(7): 981-9.
- 24 23 19. Szmunes W, Prince AM, Cherubin CE. Serum hepatitis antigen (SH) carrier state: relation to ABO blood  
25 24 groups. *Br Med J* 1971; **2**(5755): 198-9.
- 26 25 20. Szmunes W, Hirsch RL, Prince AM, Levine RW, Harley EJ, Ikram H. Hepatitis B surface antigen in  
27 26 blood donors: further observations. *J Infect Dis* 1975; **131**(2): 111-8.
- 28 27 21. Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. Seroprevalence and risk factors for  
29 28 hepatitis B virus infection among general population in Northern India. *Arq Gastroenterol* 2008; **45**(2): 137-  
30 29 40.
- 31 30 22. WHO. Global health sector strategy on viral hepatitis 2016-2021. 2016.  
32 31 <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>.
- 33 32 23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of  
34 33 nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**(9): 603-5.
- 35 34 24. Rostom A, Dube C, Cranney A, et al. Agency for Healthcare Research and Quality (US). 2004 Sep.  
36 35 <https://www.ncbi.nlm.nih.gov/books/NBK35156/>.
- 37 36 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**(11): 1539-  
38 37 58.
- 39 38 26. World Bank. World Bank list of economies (July 2016). 2016.  
40 39 <http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS>.
- 41 40 27. Terrier E, Simonneau M, Jaulmes B. Screening blood donors for Australia antigen carriers at the Broussais  
42 41 hospital. *Vox Sang* 1970; **19**(3): 352-6.
- 43 42 28. Leski M, Grivaux C, Courouce-Pauty AM. Australia antigen in hemodialysis and renal transplantation  
44 43 units. *Vox Sang* 1970; **19**(3): 359-68.
- 45 44 29. Zuberi SJ, Lodi TZ. Hepatitis B antigen in blood donors in Karachi. 1974. *J Pak Med Assoc* 2004; **54**(8  
50 45 Suppl): S39-40.

- 1 30. Vale TG, Thomas HN, Hawkes RA, Kelly A. ABO blood groups and hepatitis B antigen and antibody.  
2 *Aust N Z J Med* 1974; **4**(1): 1-2.
- 3 31. Moore HH, Campling M, Hart GE. A comparison of hepatitis B antigen and blood groups in African  
4 donors. *Cent Afr J Med* 1975; **21**(8): 175-6.
- 5 32. Lenka MR, Ghosh E, Bhattacharyya PK. ABO blood groups in relation to hepatitis-B surface antigen  
6 (Australia antigen). *Trans R Soc Trop Med Hyg* 1981; **75**(5): 688-90.
- 7 33. Nath N, Mushahwar IK, Fang CT, Berberian H, Dodd RY. Antibodies to Delta-Antigen in Asymptomatic  
8 Hepatitis-B Surface Antigen-Reactive Blood-Donors in the United-States and Their Association with Other  
9 Markers of Hepatitis-B Virus. *Am J Epidemiol* 1985; **122**(2): 218-25.
- 10 34. Kulkarni AG, Aloowooja FO, Wayo GB. Prevalence of hepatitis B surface antigen in northern Nigerian  
11 blood donors. *Vox Sang* 1986; **50**(3): 151-3.
- 12 35. Naidu AS, Rajyalakshmi K. Detection of hepatitis B surface antigen among professional blood donors in  
13 Hyderabad, India. *J Commun Dis* 1986; **18**(3): 215-8.
- 14 36. Sebastian VJ, Bhattacharya S, Ray S, Ahmad MZ. Hepatitis-B surface antigen and VDRL in healthy blood  
15 donors of Brunei Darussalam. *Singapore Med J* 1989; **30**(6): 568-70.
- 16 37. Zhu C, Zhang H, Xiong J, Gan D. Study on Relationship between ABO Blood-Type and Infection of  
17 Hepatitis Viruses. *Acta Acad Med Jiangxi* 2002; **42**: 72-3.
- 18 38. Joshi SK, Ghimire GR. Serological prevalence of antibodies to human immunodeficiency virus (HIV) and  
19 hepatitis B virus (HBV) among healthy Nepalese males--a retrospective study. *Kathmandu Univ Med J* 2003;  
20 **1**(4): 251-5.
- 21 39. El-Gilany A-H, El-Fedawy S. Bloodborne infections among student voluntary blood donors in Mansoura  
22 University, Egypt. *East Mediterr Health J* 2006; **12**(6): 742-8.
- 23 40. Rifat-uz-Zaman. Relationship between HBV-markers prevalence and promotive factors among human  
24 urban population of Bahawalpur district, Pakistan: A cross-sectional study. *Res J Pharmacol* 2009; **3**(1): 7-14.
- 25 41. Dirisu JO, Alli TO, Adegoke AO, Osazuwa F. A Survey of prevalence of serum antibodies to human  
26 immunodeficiency deficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) among blood  
27 donors. *N Am J Med Sci* 2011; **3**(1): 35-8.
- 28 42. Saeed Anwar M, Mujtaba Siddiqi G, Haq S, Ghias Khokhar N, Jaffery G. Association of blood group  
29 types to hepatitis B and hepatitis C virus infection. *Biomedica* 2011; **27**:57-61.
- 30 43. Omar AA, Noor NA, Mahmood JM. The infection with HBV and HCV and their relationship to ABO  
31 blood group among blood donors. *J Fac Med Baghdad* 2012; **54**(1): 52-6.
- 32 44. Tyagi S, Tyagi A. Possible Correlation of Transfusion Transmitted Diseases with Rh type and ABO Blood  
33 Group System. *J Clin Diagn Res* 2013; **7**(9): 1930-1.
- 34 45. Sethi B, Kumar S, Butola KS, Mishra JP, Kumar Y. Seroprevalence pattern among blood donors in a  
35 tertiary health care center. *Internet J Med Update* 2014; **9**(1): 10-5.
- 36 46. Nigam JS, Singh S, Kaur V, Giri S, Kaushal RP. The Prevalence of Transfusion Transmitted Infections in  
37 ABO Blood Groups and Rh Type System. *Hematol Rep* 2014; **6**(4): 5602.
- 38 47. Zhao Y, Zhang Y, Huang J, Gao J. Clinical analysis of detection of markers related to infectious diseases.  
39 *Chin J of Nosocomiol* 2014; **24**(14): 3635-7.
- 40 48. Siransy LK, Nanga ZY, Zaba FS, Tufa NY, Dasse SR. ABO/Rh BLOOD GROUPS AND RISK OF HIV  
41 INFECTION AND HEPATITIS B AMONG BLOOD DONORS OF ABIDJAN, COTE D'IVOIRE. *Eur J*  
42 *Microbiol Immunol* 2015; **5**(3): 205-9.
- 43 49. Navolan D, Vladareanu S, Ciohat I, et al. Prevalence of HBsAg Carrying Pregnant Women in Romania:  
44 Demographic and Behavioral Features. *Proceedings of the 49th Annual Scientific Meeting of the European*

- 1  
2 1 *Society for Clinical Investigation* 2015: 249-52.
- 3 2 50. Bisetegen FS, Bekele FB, Ageru TA, Wada FW. Transfusion-Transmissible Infections among Voluntary  
4 3 Blood Donors at Wolaita Sodo University Teaching Referral Hospital, South Ethiopia. *Can J Infect Dis Med*  
5 4 *Microbiol* 2016; (8254343).
- 6 5 51. Abate M, Wolde T. Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C  
7 6 Virus, and Syphilis among Blood Donors at Jigjiga Blood Bank, Eastern Ethiopia. *Ethiop J Health Sci* 2016;  
8 7 **26**(2): 155-62.
- 9 8 52. Bharadva S, Vachhani J, Dholakiya S. ABO and Rh association to transfusion transmitted infections  
10 9 among healthy blood donors in Jamnagar, Gujarat, India. *J Res Med Dent Sci* 2016; **4**(1): 58-62.
- 11 10 53. Naseri Z, Ghannad MS, Hosseini SM, Roshanaei G, Nejad ASM, Mohammadi A. Evaluation of  
12 11 Accompaniment of ABO Blood Groups System and Rhesus blood group types with Infection to Hepatitis B  
13 12 Virus and Hepatitis C Virus in Hamadan, Iran. *Int J of Med Res & Health Sci* 2016; **5**(4): 1-5.
- 14 13 54. Memon FA, Ujjan ID, Memon AI, Shaikh AR, Rao AR, Naz A. Seroprevalence of transfusion transmitted  
15 14 infections among different blood group donors at blood bank LUMHS, Hyderabad; 2017.
- 16 15 55. Batool Z, Durrani SH, Tariq S. Association Of Abo And Rh Blood Group Types To Hepatitis B, Hepatitis  
17 16 C, Hiv And Syphilis Infection, A Five Year' Experience In Healthy Blood Donors In A Tertiary Care Hospital.  
18 17 *J Ayub Med Coll Abbottabad* 2017; **29**(1): 90-2.
- 19 18 56. Ngassaki-Yoka C-D, Ndong JMN, Bisseye C. ABO, Rhesus Blood Groups and Transfusion-transmitted  
20 19 Infections among Blood Donors in Gabon. *Sudan J Med Sci* 2018; **13**(1): 12-21.
- 21 20 57. Fu X, Xu C, Cai X, Wu J. Analysis of infection status and clinical significance of infectious diseases  
22 21 before transfusion. *Chin J Nosocomiol* 2018; **28**(16): 2498-501.
- 23 22 58. Nkansah C, Serwaa D, Osei-Boakye F, Owusu-Ampomah R. Seroprevalence and trend of hepatitis  
24 23 among blood donors in a district hospital in Ghana: a nine-year retrospective, descriptive cross-sectional study.  
25 24 *J J immunoass & immunoch* 2019: 1-13.
- 26 25 59. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci  
27 26 influencing plasma levels of liver enzymes. *Am J Hum Genet* 2008; **83**(4): 520-8.
- 27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**Figure 1.** The process of study selection for the meta-analysis.





Figure 2. Forest plots by prevalence: (A) B vs. non-B; (B) O vs. non-O.



**Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



**Additional file 1:**

The electronic search strategy for PubMed:

(((((hepatitis B[MeSH Terms]) OR hepatitis B virus[MeSH Terms]) OR Hepatitis B Surface Antigens[MeSH Terms]) OR hepatitis B[Text Word]) OR hepatitis B virus[Text Word]) OR HBV[Text Word]) OR HBsAg[Text Word]) AND ( "0001/01/01"[PDat] : "2019/11/30"[PDat] ) AND ((((((ABO Blood-Group System[MeSH Terms]) OR Rh-Hr Blood-Group System[MeSH Terms]) OR blood type[Text Word]) OR blood group[Text Word]) OR ABO[Text Word]) OR Rh[Text Word]) OR rhesus[Text Word]) AND ( "0001/01/01"[PDat] : "2019/11/30"[PDat] )

For peer review only

## Additional file 2:

Table S1-1: Quality assessment for cross-sectional studies by Agency for Healthcare Research and Quality table.

Author	1	2	3	4	5	6	7	8	9	10	11	Total
Terrier, E.1970 <sup>27</sup>	Y	N	N	U	U	Y	/	N	/	Y	Y	4
Leski, M.1970 <sup>28</sup>	Y	N	Y	N	U	Y	N	N	/	Y	Y	5
Szmunn, W.1971 <sup>19</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zuberi, S. J.1974 <sup>29</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Vale, T. G.1974 <sup>30</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Moore, H. H.1975 <sup>31</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Szmunn, W.1975 <sup>20</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Lenka, M. R.1981 <sup>32</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Nath, N.1985 <sup>33</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Kulkarni, A. G.1986 <sup>34</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Naidu, A. S.1986 <sup>35</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Sebastian, V. J.1989 <sup>36</sup>	Y	N	N	N	U	Y	/	N	N	Y	Y	4
Zhu, C.2002 <sup>37</sup>	Y	N	Y	Y	U	Y	N	N	N	N	Y	5
Joshi, S. K.2003 <sup>38</sup>	Y	Y	Y	N	U	Y	/	N	/	Y	Y	6
El-Gilany, A-H.2006 <sup>39</sup>	Y	Y	Y	N	U	Y	/	N	Y	N	Y	6
Behal, R.2008 <sup>21</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Rifat-uz-Zaman2009 <sup>40</sup>	Y	Y	Y	/	U	N	/	N	Y	Y	Y	6
Dirisu, J. O.2011 <sup>41</sup>	Y	Y	Y	Y	U	Y	/	N	/	Y	Y	7
Saeed Anwar, M.2011 <sup>42</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Omar, A. A. 2012 <sup>43</sup>	Y	N	Y	N	U	Y	/	N	/	Y	Y	5
Tyagi, S.2013 <sup>44</sup>	Y	Y	Y	N	U	Y	/	N	Y	Y	Y	7
Sethi, B.2014 <sup>45</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Mohammadali, F.2014 <sup>18</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Nigam, J. S.2014 <sup>46</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zhao, Y.2014 <sup>47</sup>	Y	N	Y	N	U	Y	/	N	Y	Y	Y	6
Siransy, L. K.2015 <sup>48</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Navolan, D.2015 <sup>49</sup>	Y	Y	N	N	U	Y	N	N	N	Y	Y	5
Bisetegen, F. S.2016 <sup>50</sup>	Y	Y	Y	N	U	Y	/	N	N	Y	Y	6
Abate, M.2016 <sup>51</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Bharadva, S.2016 <sup>52</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Naseri, Z.2016 <sup>53</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Memon, F. A.2017 <sup>54</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Liu, J.2017 <sup>17</sup>	Y	Y	Y	Y	U	Y	Y	Y	Y	Y	Y	9
Batool, Z.2017 <sup>55</sup>	Y	Y	Y	Y	U	Y	U	N	U	N	Y	6
Ngassaki-Y, C-D.2018 <sup>56</sup>	Y	Y	Y	Y	U	Y	/	N	/	Y	Y	7
Fu, X.2018 <sup>57</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Nkansah, C.2019 <sup>58</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8

Y, Yes; N, No; U, Unclear; /, not applicable.

Note:

Item 1: Define the source of information (survey, record review).

- Item 2: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications.
- Item 3: Indicate time period used for identifying patients.
- Item 4: Indicate whether or not subjects were consecutive if not population-based.
- Item 5: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants.
- Item 6: Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements).
- Item 7: Explain any patient exclusions from analysis.
- Item 8: Describe how confounding was assessed and/or controlled.
- Item 9: If applicable, explain how missing data were handled in the analysis.
- Item 10: Summarize patient response rates and completeness of data collection.
- Item 11: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

**Table S1-2:** Quality assessment for cohort studies by Newcastle-Ottawa Scales table.

Author	Selection	Comparability	Outcome	Total
T. T. Lao 2014 <sup>16</sup>	3	1	3	7

Note:

Selection: 1) Representativeness of the exposed cohort; 2) Selection of the non-exposed cohort; 3) Ascertainment of exposure; 4) Demonstration that outcome of interest was not present at start of study.

Comparability: 1) Comparability of cohorts on the basis of the design or analysis.

Outcome: 1) Assessment of outcome; 2) Was follow-up long enough for outcomes to occur; 3) Adequacy of follow up of cohorts.

**Meta-analysis of Observational Studies in Epidemiology (MOOSE) Checklist**

**ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis**

Criteria	Brief description of how the criteria were handled in the meta-analysis
<b>Reporting of background should include</b>	
√ Problem definition	Controversy remains with regard to whether blood group is related to HBV infection and which antigen is a protective or a risk factor.
√ Hypothesis statement	We performed a systematic review and meta-analysis to elucidate the association between ABO blood groups and HBV infection risk.
√ Description of study outcomes	HBV infection
√ Type of exposure or intervention used	ABO blood group
√ Type of study designs used	Cross-sectional or cohort studies
√ Study population	Unrestricted
<b>Reporting of search strategy should include</b>	
√ Qualifications of searchers	Two reviewers (SZ and WJ) searched for articles independently.
√ Search strategy, including time period included in the synthesis and keywords	Available online before December 1, 2019, from five databases including PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central using the following keywords: "hepatitis B" OR "hepatitis B virus" OR "HBV" OR "HBsAg" and "blood type" OR "blood group" OR "ABO" OR "Rh" OR "rhesus".
√ Effort to include all available studies	Highly relevant reference articles were also searched by reviewing the list of references.
√ Databases and registries searched	PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central
√ Search software used, name and version, including special features	We did not employ a search software. Endnote was used to merge retrieved citations.
√ Use of hand searching	Highly relevant reference articles were also searched by reviewing the list of references.
√ List of citations located and those excluded, including justifications	Figure 1
√ Method of addressing articles published in languages other than English	There was no limitation of language.
√ Method of handling abstracts and unpublished studies	We did not include unpublished studies. If abstract could provide full information, it was included.
√ Description of any contact with authors	When needed, we contacted the original author

		for the data, but nobody responded to us.
	<b>Reporting of methods should include</b>	
√	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	Detailed inclusion and exclusion criteria are described in the paper.
√	Rationale for the selection and coding of data	(1) the basic information of the studies including first author, publication year, journal, survey time, study design; (2) the characteristics of the study population including country, income group, race, population type (e.g., blood donors, patients, general population), sample size, the number of HBV-infected and uninfected subjects, age range, mean age, sex ratio; (3) the outcome measure: the number of HBV-infected and uninfected subjects in each ABO blood group; and (4) the author's general conclusions.
√	Documentation of how data were classified and coded	The prevalence of HBV infection was calculated in each study based on the number of HBV-infected and uninfected subjects. Studies were divided into Caucasian, Asian, and Negroid subgroups depending on the major national race and divided into high, upper middle, lower middle and low income groups according to the World Bank list of economies.
√	Assessment of confounding	Subgroup analyses were performed by HBV prevalence, race, sample size, population, income group, study type, and publication year.
√	Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results	The quality of selected cohort studies were assessed using the Newcastle-Ottawa Scales (NOS). The quality of the selected cross-sectional studies were assessed using an 11-item checklist recommended by the Agency for Healthcare Research and Quality (AHRQ).
√	Assessment of heterogeneity	$I^2$ was used to evaluate heterogeneity among the studies. When $I^2 \leq 50\%$ , the included studies were considered to have little heterogeneity; when $I^2 > 50\%$ , the included studies were considered to have substantial heterogeneity.
√	Description of statistical methods in sufficient detail to be replicated	RRs and 95% CIs (A vs. non-A, B vs. non-B, O vs. non-O, AB vs. non-AB) were pooled by using of random-effect models with the estimate of heterogeneity being taken from the Mantel-Haenszel model, and $P < 0.05$ was

		deemed significantly.
√	Provision of appropriate tables and graphics	Figure 2,3 and Table 2
<b>Reporting of results should include</b>		
√	Graphic summarizing individual study estimates and overall estimate	Table 1 and Table 2
√	Table giving descriptive information for each study included	Table 1
√	Results of sensitivity testing	Table 2
√	Indication of statistical uncertainty of findings	RR, 95% CI, I <sup>2</sup> and P
<b>Reporting of discussion should include</b>		
√	Quantitative assessment of bias	Results of subgroup analyses and sensitive analyses were discussed.
√	Justification for exclusion	(1) the article was not relevant to the subject of the study (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies, where if studies overlapped, we only included the last published; and (4) duplicated studies, where if the same study was found in different databases, we only included the article once.
√	Assessment of quality of included studies	Table S1-1 and Table S1-2
<b>Reporting of conclusions should include</b>		
√	Consideration of alternative explanations for observed results	First, although we performed subgroup analyses, analyses of previous studies have revealed that the heterogeneity cannot be ignored. Second, the analyzed studies lacked the basic information of the ethnicity data and the prevalence of different HBV genotypes. Third, few published studies on the association between HBV infection and blood group have controlled HBV infection related risk factors such as family history of HBV infection, age group, blood transfusion, and acupuncture, thus we were not able to conduct the corresponding subgroup analyses.
√	Generalization of the conclusions	In conclusion, blood group B was associated with a lower risk of HBV infection.
√	Guidelines for future research	In the future, more researches are needed to clarify the precise role of the ABO blood group in HBV infection to address the global question of HBV infection.
√	Disclosure of funding source	This study was supported by the National Natural Science Foundation of China (Grant No. 71874003 and No. 81703240).

# BMJ Open

## ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2019-034114.R2
Article Type:	Original research
Date Submitted by the Author:	10-Jan-2020
Complete List of Authors:	Jing, wenzhan; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Zhao, Siyu; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Jue; Peking University, School of Public Health, Department of Epidemiology & Biostatistics Liu, Min; Peking University, School of Public Health, Department of Epidemiology & Biostatistics
<b>Primary Subject Heading</b>:	Epidemiology
Secondary Subject Heading:	Gastroenterology and hepatology, Global health, Public health, Infectious diseases
Keywords:	Hepatitis B virus, ABO blood group, meta-analysis

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1 **Title page**

2 **Title: ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis**

3 **Authors:** Wenzhan Jing, Siyu Zhao, Jue Liu \*, Min Liu \*

4 1 Wenzhan Jing, Department of Epidemiology and Biostatistics, School of Public Health, Peking

5 University; No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jingwenzhan@bjmu.edu.cn

6 2 Siyu Zhao, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

7 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: zhaosiyu@bjmu.edu.cn

8 3 Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

9 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: jue Liu@bjmu.edu.cn

10 4 Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University;

11 No.38 Xueyuan Road, Haidian District, Beijing, China. E-mail: liumin@bjmu.edu.cn

12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

14 **Correspondence to:**

15 Prof. Min Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

16 Beijing 100191, China. (Tel: 86-10-82805146, Fax: 86-10-82805146, Email: liumin@bjmu.edu.cn);

17 Prof. Jue Liu, Department of Epidemiology and Biostatistics, School of Public Health, Peking University,

18 Beijing 100191, China. (Tel: 86-10-82801528, Fax: 86-10-82801528, Email: jue Liu@bjmu.edu.cn)

# 1 ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and Meta-Analysis

## 2 Abstract

3 **Objective** Hepatitis B virus (HBV) infection is a major public health problem worldwide. Several studies  
4 have reported that ABO blood groups may be associated with HBV infection. However, its association is  
5 still controversial. We performed a meta-analysis to investigate whether ABO blood groups were  
6 associated with HBV infection.

7 **Design** Systematic review and meta-analysis.

8 **Data sources** Relevant studies available before December 1, 2019 were identified by searching PubMed,  
9 EMBASE, Web of Science, ScienceDirect, and the Cochrane Library.

10 **Eligibility criteria** All cross-sectional or cohort studies that the data of ABO blood group distribution and  
11 HBV infection could be extracted.

12 **Data extraction and synthesis** Studies were identified and extracted by two reviewers independently.  
13 Risk ratios (RRs) and 95% confidence intervals (CIs) were pooled by random-effect models to quantify  
14 this association.

15 **Results** Thirty-eight eligible articles including 241,868 HBV-infected subjects and 6,487,481 uninfected  
16 subjects were included. Overall, the risk of HBV infection had decreased by 8% in subjects with blood  
17 group B when compared with blood group non-B (RR = 0.92, 95% CI: 0.86–0.98). In the subgroup  
18 analyses, the inverse relationship between blood group B and HBV infection remained stable in higher  
19 endemic areas (HBV prevalence  $\geq$  5%), Asian people, larger sample size studies ( $\geq$  2000), general  
20 population and blood donors, lower middle income group and studies published before 2010 years.  
21 Additionally, subjects with blood group O had a 12% increased risk of HBV infection (RR = 1.12, 95%  
22 CI:1.01-1.24) in higher endemic areas. In the sensitivity analysis, the pooled risk estimates of blood group  
23 B and HBV infection were still stable.

24 **Conclusions** Our data suggested that the blood group B was associated with a lower risk of HBV infection.  
25 More researches are needed to clarify the precise role of ABO blood group in HBV infection to address  
26 the global question of HBV infection.

## 27 Strengths and limitations of this study

28 ➤ The breadth of the comprehensive systematic literature search is a strength of this study.

1  
2 1 ➤ To our knowledge, this was the first meta-analysis of the association between ABO blood groups and  
3  
4 2 HBV infection.

5  
6  
7 3 ➤ Although we performed subgroup analyses, the heterogeneity cannot be ignored because few  
8  
9 4 published studies described the related risk factors of HBV infection in detail.

## 10 11 5 **Introduction**

12  
13  
14 6 Hepatitis B virus (HBV) infection is a major public health problem worldwide,<sup>1</sup> especially in Africa and  
15  
16 7 the Western Pacific Region.<sup>2</sup> According to the global hepatitis report in 2017, it is estimated that 257  
17  
18 8 million people, 3.5% of the general population, are living with HBV infection worldwide with about 0.88  
19  
20 9 million deaths caused by complications of chronic HBV infection every year.<sup>2</sup> HBV infection has caused  
21  
22 10 a high societal burden globally.<sup>1,2</sup>

23  
24  
25 11 The ABO blood group system, the most extensively investigated erythrocyte antigen system,<sup>3</sup> is widely  
26  
27 12 used in clinical practice, and influences the host susceptibility.<sup>4,5</sup> As an easily accessible factor in an  
28  
29 13 individual's genetic makeup, ABO blood groups have been not only statistically but also biologically  
30  
31 14 associated with many chronic diseases such as vascular disease,<sup>6</sup> coronary heart disease,<sup>7</sup> and  
32  
33 15 tumorigenesis.<sup>3,4,8</sup> For instance, by expressing on N-glycans of von Willebrand factor (VWF), ABH  
34  
35 16 antigens (H antigen is the biosynthetic precursor to A and B antigens<sup>5</sup>) impact the half-life of VWF, so  
36  
37 17 VWF survival in O subjects is significantly shorter versus (vs.) in non-O subjects.<sup>9-11</sup> Therefore, because  
38  
39 18 of the lower VWF levels, O subjects have lower risk of venous thromboembolism.<sup>10</sup> Recently, a meta-  
40  
41 19 analysis also found that hepatocellular carcinoma (HCC) patients might have a lower proportion of O  
42  
43 20 subjects than healthy subjects.<sup>12</sup> Meanwhile, the association between ABO blood groups and host  
44  
45 21 susceptibility to infectious diseases (such as helicobacter pylori, plasmodium falciparum, and human  
46  
47 22 immunodeficiency virus, etc.) has been shown in several studies.<sup>5,13</sup> Previous studies have found the  
48  
49 23 reasons for this association were that ABO antibodies are part of the innate immune system against some  
50  
51 24 bacteria, parasites and enveloped viruses,<sup>5</sup> and blood antigens are important as receptors for immune and  
52  
53 25 inflammation response,<sup>14,15</sup> which means the biologic association between ABO blood groups and HBV  
54  
55 26 infection probably exist.

56  
57 27 Epidemiologic studies have explored the relationship between blood group and HBV infection, however,  
58  
59 28 the results have been contradictory. Lao et al.<sup>16</sup> found that HBV prevalence was lower in blood group B  
60

(9.6%) and AB (9.1%), but higher in blood group O (10.2%). Liu et al.<sup>17</sup> suggested that blood group O was associated with increased HBV infection. Mohammadali et al.<sup>18</sup> found that the percentage of hepatitis B surface antigen (HBsAg) was lower in donors who had blood group O. However, Szmuness et al.<sup>19,20</sup> and Behal et al.<sup>21</sup> failed to find a link between blood group and HBV infection. Thus, controversy remains with regard to whether blood group is related to HBV infection and which antigen is a protective or a risk factor. We performed a systematic review and meta-analysis to elucidate the association between ABO blood groups and HBV infection risk to provide evidence on improving blood safety and preventing HBV infection, which can help to achieve the target of eliminating HBV as an international public health challenge.<sup>22</sup>

## Materials and methods

### Data sources and search strategy

Two reviewers (SZ and WJ) searched independently for articles, which were available online before December 1, 2019, from five databases including PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central using the following keywords: “hepatitis B” OR “hepatitis B virus” OR “HBV” OR “HBsAg” and “blood type” OR “blood group” OR “ABO” OR “Rh” OR “rhesus”. Meanwhile, highly relevant reference articles were also searched by reviewing the list of references. There was no limitation of language or region. The full electronic search strategy for PubMed are shown in Additional file 1.

### Inclusion and exclusion criteria

Articles were included in the meta-analysis if: (1) the article was a cross-sectional or cohort study; (2) the data of the ABO blood group distribution and HBV infection could be extracted to calculate the risk ratio (RR), which meant that the number of HBV-infected and uninfected subjects were reported in each blood group. The exclusion criteria were as follows: (1) the article was not relevant to the subject of the study (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies, where if studies overlapped, we only included the last published; and (4) duplicated studies, where if the same study was found in different databases, we only included the article once.

According to the inclusion and exclusion criteria, studies were identified by two reviewers (SZ and WJ) independently. Discrepancies were solved by consensus or decided by a third reviewer (JL).

## 1 **Data extraction and quality assessment**

2 According to the piloted forms, four main parts of the information were extracted independently by two  
3 reviewers (SZ and WJ) from the selected studies: (1) the basic information of the studies including first  
4 author, publication year, journal, survey time, study design; (2) the characteristics of the study population  
5 including country, income group, race, population type (e.g., blood donors, patients, general population),  
6 sample size, the number of HBV-infected and uninfected subjects, age range, mean age, sex ratio; (3) the  
7 outcome measure: the number of HBV-infected and uninfected subjects in each ABO blood group; and  
8 (4) the author's general conclusions.

9 The quality of selected cohort studies were assessed using the Newcastle-Ottawa Scales (NOS) with a  
10 score ranging from 0 to 9.<sup>23</sup> A score of 4–6 indicated moderate quality, and a score of 7–9 indicated high  
11 quality. The quality of the selected cross-sectional studies were assessed using an 11-item checklist  
12 recommended by the Agency for Healthcare Research and Quality (AHRQ)<sup>24</sup> with a score ranging from 0  
13 to 11. A score of 4–7 indicated moderate quality, and a score of 8–11 indicated high quality.

## 14 **Statistical analysis**

15 The main outcome was the prevalence of HBV infection (defining as HBsAg-positive) in our meta-  
16 analysis. The relationship between the ABO blood groups and HBV infection was quantified using RR  
17 values and the corresponding 95% confidence intervals (CIs). RRs and 95% CIs (A vs. non-A, B vs. non-B,  
18 O vs. non-O, AB vs. non-AB) were pooled by using of random-effect models with the estimate of  
19 heterogeneity being taken from the Mantel-Haenszel model, and a  $p < 0.05$  was deemed significant. Between-  
20 study heterogeneity was evaluated with the  $I^2$  statistic. When  $I^2 \leq 50\%$ , the included studies were  
21 considered to have little heterogeneity; when  $I^2 > 50\%$ , the included studies were considered to have  
22 substantial heterogeneity.<sup>25</sup>

23 Subgroup analyses were performed by HBV prevalence, race, sample size, population, income group,  
24 study type, and publication year. The prevalence of HBV infection was calculated in each study based on  
25 the number of HBV-infected and uninfected subjects. Studies were divided into Caucasian, Asian, and  
26 African subgroups depending on the major national race and divided into high, upper middle, lower middle  
27 and low income groups according to the World Bank list of economies.<sup>26</sup> Sensitivity analyses were  
28 performed by excluding large sample size studies orderly or at the same time, which dominated the results

1 of the meta-analysis. Publication bias was evaluated by funnel plots and two-sided Egger's tests, and a p  
2 < 0.05 was deemed significant. All statistical analyses were performed with STATA version 12.0.

### 3 **Patient and public involvement**

4 There was no direct patient or public involvement in this review.

## 5 **Results**

### 6 **Study selection and study characteristics**

7 A total of 4486 articles (4476 from database and 10 from other sources) were searched, of which 1584  
8 were duplicate results. After reading the abstracts, 2211 were deemed irrelevant and three reviews were  
9 excluded. After reading the full text, 650 articles were excluded, of which 610 were irrelevant articles, and  
10 40 studies provided insufficient information. Eventually, 38 eligible articles were included in the meta-  
11 analysis. A flow-chart of study selection was shown as Figure 1.

12  
13 **Insert Figure 1.** The process of study selection for the meta-analysis.

14  
15 The basic characteristics of the selected studies are shown in Table 1. All selected articles were  
16 observational studies and published between 1970 and 2019. A total of 6,487,481 subjects were included  
17 with 241,868 HBV-infected subjects and 6,245,613 uninfected subjects. Among the Caucasian, Asian, and  
18 African population, there were 23, 7, and 8 studies, respectively. In addition, there were 7, 9, 18 and 4  
19 study in high income, upper middle income, lower middle income and low income group, respectively.  
20 Furthermore, there were 14 studies in higher (HBV prevalence  $\geq 5\%$ ) endemic and 24 studies in lower  
21 (HBV prevalence  $< 5\%$ ) endemic areas, respectively. Meanwhile, there were 37 cross-sectional studies and  
22 1 cohort study in the meta-analysis.

23

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
**Table 1.** Characteristics of the included studies.

Author	Income group	Race	Population	Sample size	HBV infection (n/%)				
					Total	A, non-A <sup>a</sup>	B, non-B <sup>a</sup>	AB, non-AB <sup>a</sup>	O, non-O <sup>a</sup>
Terrier, E.1970 <sup>27</sup>	High	Caucasian	Blood donors	5968	55/0.92	9/0.37, 46/1.31	4/0.66, 51/0.95	2/0.78, 53/0.93	40/1.51, 15/0.45
Leski, M.1970 <sup>28</sup>	High	Caucasian	Patients	155	34/21.94	16/23.19, 18/20.93	4/28.57, 30/21.28	0/0, 34/22.67	14/20.9, 20/22.73
Szmunness, W.1971 <sup>19</sup>	High	Caucasian	Blood donors	8096	177/2.19	61/2.06, 116/2.26	25/2.21, 152/2.18	13/3.57, 164/2.12	78/2.14, 99/2.23
Zuberi, S. J.1974 <sup>29</sup>	Lower middle	Caucasian	Blood donors	1111	38/3.42	9/3.36, 29/3.44	5/1.23, 33/4.69	2/3.64, 36/3.41	22/5.77, 16/2.19
Vale, T. G.1974 <sup>30</sup>	Lower middle	African	General	836	40/4.78	18/5.61, 22/4.27	6/4.11, 34/4.93	5/4.59, 35/4.81	11/4.23, 29/5.03
Moore, H. H.1975 <sup>31</sup>	Low	Caucasian	Blood donors	14916	495/3.32	127/3.48, 368/3.27	103/3.21, 392/3.35	17/3.1, 478/3.33	248/3.3, 247/3.33
Szmunness, W.1975 <sup>20</sup>	High	Caucasian	Blood donors	51019	58/0.11	22/0.11, 36/0.11	5/0.08, 53/0.12	4/0.16, 54/0.11	27/0.12, 31/0.11
Lenka, M. R.1981 <sup>32</sup>	Lower middle	Caucasian	Blood donors	500	24/4.8	12/9.3, 12/3.23	8/4.08, 16/5.26	0/0, 24/5.25	4/3.03, 20/5.43
Nath, N.1985 <sup>33</sup>	Lower middle	Caucasian	Blood donors	1585	68/4.29	22/4.03, 46/4.44	9/3.35, 59/4.48	3/4.17, 65/4.30	34/4.87, 34/3.83
Kulkarni, A. G.1986 <sup>34</sup>	Lower middle	African	Blood donors	1860	165/8.87	51/13.11, 114/7.85	17/3.11, 148/11.27	18/18.75, 147/8.33	79/9.54, 86/8.33
Naidu, A. S.1986 <sup>35</sup>	High	Caucasian	Blood donors	1029	145/14.09	49/20.08, 96/12.40	42/12.39, 103/14.93	11/17.74, 134/13.86	43/11.20, 102/15.81
Sebastian, V. J.1989 <sup>36</sup>	Upper middle	Asian	Blood donors	3276	134/4.09	30/4.17, 104/4.08	30/3.50, 104/4.30	10/4.76, 124/4.04	64/4.30, 70/3.91
Zhu, C.2002 <sup>37</sup>	Low	Asian	Blood donors	8683	153/1.76	44/1.62, 109/1.83	30/1.37, 123/1.89	18/2.59, 135/1.69	61/1.98, 92/1.64
Joshi, S. K.2003 <sup>38</sup>	Lower middle	Asian	General	613	17/2.77	4/2.09, 13/3.08	5/2.86, 12/2.74	1/2.13, 16/2.83	7/3.5, 10/2.42
El-Gilany, A-H.2006 <sup>39</sup>	Lower middle	Caucasian	Blood donors	2157	93/4.31	27/3.42, 66/4.87	19/3.85, 74/4.45	12/5.88, 81/4.15	35/5.23, 58/3.90
Behal, R.2008 <sup>21</sup>	Lower middle	Caucasian	Blood donors	20000	450/2.25	106/2.30, 344/2.24	174/2.34, 276/2.20	38/1.87, 412/2.29	132/2.23, 318/2.26
Rifat-uz-Zaman2009 <sup>40</sup>	Lower middle	Caucasian	General	1464	93/6.35	5/3.01, 88/6.90	35/6.63, 58/6.20	23/6.99, 70/6.17	30/6.80, 63/6.16
Dirisu, J. O.2011 <sup>41</sup>	Lower middle	African	Blood donors	427	200/46.84	32/45.71, 168/47.06	39/52, 161/45.74	1/33.33, 199/46.93	128/45.88, 72/48.65
Saeed Anwar, M.2011 <sup>42</sup>	Upper middle	Caucasian	Blood donors	16695	467/2.80	103/2.60, 364/2.86	139/2.31, 328/3.07	17/2.64, 450/2.80	208/3.42, 259/2.44
Omar, A. A. 2012 <sup>43</sup>	Lower middle	Caucasian	Blood donors	430	71/16.51	15/12.5, 56/18.06	21/21.43, 50/15.06	3/5.36, 68/18.18	32/20.51, 39/14.23
Tyagi, S.2013 <sup>44</sup>	Lower middle	Caucasian	Blood donors	6000	95/1.58	27/1.87, 68/1.49	27/1.27, 68/1.75	9/1.98, 86/1.55	32/1.62, 63/1.57
Sethi, B.2014 <sup>45</sup>	Upper middle	Caucasian	Blood donors	7884	50/0.63	15/0.60, 35/0.65	10/0.41, 40/0.74	11/1.28, 39/0.56	14/0.68, 36/0.62
Mohammadali, F.2014 <sup>18</sup>	Lower middle	Caucasian	Blood donors	2028068	7839/0.39	2553/0.40, 5286/0.38	1952/0.40, 5887/0.38	627/0.41, 7212/0.38	2707/0.36, 5132/0.40
Nigam, J. S.2014 <sup>46</sup>	High	Caucasian	Blood donors	4128	40/0.97	12/1.17, 28/0.90	11/0.75, 29/1.09	2/0.50, 38/1.02	15/1.22, 25/0.86
Lao, T. T.2014 <sup>16 b</sup>	Upper middle	Asian	General	78705	7786/9.89	2038/9.90, 5748/9.97	1991/9.60, 5795/10.00	468/9.11, 7318/9.95	3289/10.20, 4497/9.68
Zhao, Y.2014 <sup>47</sup>	Lower middle	Asian	Patients	500	66/13.20	17/11.18, 49/14.71	16/9.82, 50/14.84	15/16.67, 51/12.44	18/18.95, 48/11.85
Siransy, L. K.2015 <sup>48</sup>	Lower middle	African	Blood donors	59514	4119/6.92	947/7.15, 3172/6.86	941/6.78, 3178/6.96	187/6.77, 3932/6.93	2044/6.9, 2075/6.94
Navolan, D.2015 <sup>49</sup>	Upper middle	Caucasian	General	1385	33/2.38	15/2.42, 18/2.37	7/3.11, 26/2.24	4/3.54, 29/2.28	7/1.64, 26/2.71
Bisetegen, F. S.2016 <sup>50</sup>	Lower middle	African	Blood donors	390	37/9.49	7/6.73, 30/10.49	10/12.99, 27/8.63	2/22.22, 35/9.19	18/9, 19/10
Abate, M.2016 <sup>51</sup>	Upper middle	African	Blood donors	6827	647/9.48	114/5.66, 533/11.10	54/5.45, 593/10.16	9/4.27, 638/9.64	470/13.02, 177/5.50
Bharadva, S.2016 <sup>52</sup>	Lower middle	Caucasian	Blood donors	41909	237/0.57	62/0.63, 175/0.55	85/0.58, 152/0.56	22/0.55, 215/0.57	68/0.51, 169/0.59
Naseri, Z.2016 <sup>53</sup>	High	Caucasian	Blood donors	228409	640/0.28	208/0.29, 432/0.28	180/0.34, 460/0.26	42/0.24, 598/0.28	210/0.25, 430/0.30
Memon, F. A.2017 <sup>54</sup>	Lower middle	Caucasian	Blood donors	4683	66/1.41	15/1.37, 51/1.42	21/1.53, 45/1.36	9/2.94, 57/1.30	21/1.10, 45/1.63
Liu, J.2017 <sup>17</sup>	Lower middle	Asian	General	3827125	215455/5.63	64811/5.55, 150644/5.71	58286/5.18, 157169/5.82	18707/5.06, 196748/5.69	73651/6.34, 141804/5.32
Batool, Z.2017 <sup>55</sup>	Low	Caucasian	Blood donors	41084	969/2.36	321/2.72, 648/2.22	289/2.21, 680/2.43	82/2.13, 887/2.38	277/2.24, 692/2.41
Ngassaki-Y, C-D.2018 <sup>56</sup>	Upper middle	African	Blood donors	4744	81/1.71	-	-	-	34/1.22, 47/2.41
Fu, X.2018 <sup>57</sup>	Upper middle	Asian	Patients	2000	389/19.45	105/21.43, 284/18.81	89/18.94, 300/19.61	59/21.85, 330/19.08	136/17.66, 253/20.57
Nkansah, C.2019 <sup>58</sup>	Lower middle	African	Blood donors	3306	342/10.34	48/11.76, 294/10.21	63/9.35, 279/10.67	1/3.33, 341/10.47	230/10.48, 112/10.07

<sup>a</sup> The number of HBV infected people in the X blood group/HBV prevalence (%) in the X blood group; the number of HBV infected people in the non-X blood group/HBV prevalence (%) in the non-X blood group. <sup>b</sup> A cohort study.

1 The HBV infection prevalence in the 38 eligible articles ranged from 0.11% to 46.84%, and the HBV  
2 infection prevalence of blood group A, B, AB, O ranged from 0.11% to 45.71%, 0.08% to 52.00%, 0.00%  
3 to 33.33%, and 0.12% to 45.88%, respectively. The results of the quality assessment are shown in  
4 Additional file 2, with 15 high quality studies and 23 moderate quality studies. The score of the 37 articles  
5 assessed by AHRQ ranged from 3 to 9, while 14 of them were of high-quality with a score from 8 to 9,  
6 and 23 of them were of moderate-quality with a score from 4 to 7 (Table S1-1). The article assessed by  
7 NOS scored 7 and was of high-quality (Table S1-2).

### 8 **Main, subgroup, and sensitivity analyses**

9 Overall, the risk of HBV infection had decreased by 8% in subjects with blood group B when compared  
10 with blood group non-B (RR = 0.92, 95% CI: 0.86–0.98). However, blood groups A, O and AB were not  
11 significantly associated with an HBV infection risk (Table 2). The results of the subgroup analyses were  
12 shown in Table 2. In the subgroup analyses, the relationship between blood group B and HBV infection  
13 remained stable. The inverse relationship between blood group B and HBV infection was still observed in  
14 the higher endemic areas (HBV prevalence  $\geq$  5%), Asian people, studies with larger sample sizes ( $\geq$   
15 2000), general population and blood donors, lower middle income group, and articles published before  
16 2010 years (Table 2).



1

2 **Table 2.** The main, subgroup and sensitivity analyses.

Subgroup	No. of studies	Sample size	B vs. Non-B		O vs. Non-O		A vs. Non-A		AB vs. Non-AB	
			RR (95% CI)	p value	RR (95% CI)	p value	RR (95% CI)	p value	RR (95% CI)	p value
All studies	38	6487481	0.92 (0.86,0.98)	0.007	1.07 (1.01,1.15)	0.082	1.01 (0.96, 1.07)	0.728	1.04 (0.95,1.13)	0.419
HBV prevalence										
Higher endemic ( $\geq 5\%$ )	14	3983732	0.90 (0.83,0.98)	0.013	1.12 (1.01,1.24)	0.025	0.99 (0.91,1.08)	0.820	1.00 (0.89,1.14)	0.962
Lower endemic ( $< 5\%$ )	24	2503749	0.93 (0.85,1.02)	0.126	1.03 (0.93,1.15)	0.566	1.03 (0.95,1.11)	0.471	1.06 (0.95,1.18)	0.292
Race										
Caucasian	23	2488675	0.96 (0.87, 1.05)	0.386	1.04 (0.94, 1.16)	0.465	1.03 (0.94, 1.13)	0.472	1.05 (0.93, 1.18)	0.461
Asian	7	3920902	0.91(0.86, 0.97)	0.003	1.10 (0.99, 1.22)	0.075	0.98 (0.97, 0.99)	<0.001	0.96 (0.87, 1.06)	0.451
African	8	77904	0.78 (0.58, 1.05)	0.099	1.04 (0.77, 1.40)	0.803	0.99 (0.73, 1.33)	0.919	1.02 (0.62, 1.67)	0.953
Sample size										
$\geq 2000$	24	6475196	0.93 (0.87, 0.99)	0.018	1.07 (0.98, 1.16)	0.135	0.99 (0.94, 1.05)	0.795	1.00 (0.92, 1.08)	0.914
$< 2000$	14	12285	0.85 (0.64, 1.13)	0.275	1.08 (0.90, 1.29)	0.398	1.07 (0.85, 1.33)	0.577	1.20 (0.89, 1.61)	0.238
Population										
General	6	3910128	0.93 (0.87, 0.99)	0.016	1.07 (0.99, 1.15)	0.078	0.98 (0.96, 1.00)	0.035	0.89 (0.88, 0.90)	<0.001
Blood donors	29	2574698	0.89 (0.81, 0.97)	0.011	1.08 (0.97, 1.20)	0.154	1.01 (0.92, 1.10)	0.885	1.08 (0.95, 1.23)	0.248
Patients	3	2655	0.92 (0.71, 1.19)	0.517	1.04 (0.71, 1.54)	0.828	1.09 (0.91, 1.30)	0.345	1.17 (0.94, 1.46)	0.169
Income group										
High	7	148804	0.96 (0.91,1.00)	0.065	1.17 (0.95,1.44)	0.135	0.91 (0.74,1.11)	0.343	0.97 (0.84,1.13)	0.712
Upper middle	9	6101344	1.01 (0.88,1.15)	0.927	0.97 (0.82, 1.15)	0.756	1.00 (0.96,1.06)	0.791	1.02 (0.88,1.17)	0.814
Lower middle	18	214587	0.86 (0.76,0.97)	0.011	1.03 (0.93,1.13)	0.582	1.13(1.01,1.25)	0.030	1.13 (0.95,1.34)	0.173
Low	4	22746	0.88 (0.56,1.38)	0.572	1.34 (0.72, 2.48)	0.353	0.71 (0.42,1.21)	0.209	0.84 (0.43,1.64)	0.613
Study design										
Cross-sectional	37	6408776	0.91 (0.85, 0.97)	0.007	1.07 (0.98, 1.17)	0.111	1.01 (0.95,1.08)	0.780	1.06 (0.96, 1.17)	0.244
Cohort	1	78705	0.96 (0.92, 1.01)	0.098	1.05 (1.01, 1.10)	0.016	1.00 (0.95, 1.05)	0.957	0.92 (0.84, 1.00)	0.053
Publication year										
Before 2010	17	123268	0.80 (0.67, 0.96)	0.015	1.12 (0.97, 1.29)	0.112	1.02 (0.85, 1.22)	0.830	1.22 (1.01, 1.46)	0.040
After 2010	21	6364213	0.95 (0.88, 1.01)	0.106	1.05 (0.95, 1.15)	0.335	1.00 (0.94, 1.06)	0.910	0.98 (0.89, 1.07)	0.627
Sensitive analyses										
Removed Liu's study <sup>17</sup>	37	2660356	0.91 (0.85, 0.98)	0.012	1.06 (0.98, 1.15)	0.138	1.01 (0.94, 1.08)	0.816	1.06 (0.97, 1.17)	0.213
Removed Mohammedali's study <sup>18</sup>	37	4459413	0.91 (0.85, 0.97)	0.002	1.08 (1.00, 1.16)	0.044	1.01 (0.94, 1.07)	0.857	1.04 (0.95, 1.14)	0.445
Removed both Liu's and Mohammedali's study <sup>17,18</sup>	36	632288	0.90 (0.83, 0.97)	0.007	1.07 (0.98, 1.17)	0.115	1.00 (0.92, 1.09)	0.946	1.08 (0.96, 1.20)	0.211

3 RR: Risk ratio.

4

5 In higher endemic areas, subjects with blood group B had a significantly lower risk of HBV infection  
6 (RR = 0.90, 95% CI: 0.83–0.98) than the non-B group (Figure 2A), while subjects with the blood group  
7 O had a significantly higher risk of HBV infection (RR = 1.12, 95% CI: 1.01–1.24) than the non-O group  
8 (Figure 2B). According to the race of the subjects, blood group A and B were linked with decreased risk  
9 of HBV infection in the Asian population when compared to non-A and non-B, respectively (RR = 0.98,  
10 95%CI: 0.97–0.99; RR = 0.91, 95% CI: 0.86–0.97) (Table 2). However, no association was found among

1 the Caucasian or African population. In general population, blood group A, B and AB had a decreased risk  
2 of HBV infection compared to non-A, non-B and non-AB, respectively (RR = 0.98, 95%CI: 0.96–1.00;  
3 RR = 0.93, 95% CI: 0.87–0.99 and RR = 0.89, 95% CI: 0.88–0.90, respectively) (Table 2).

4  
5 **Insert Figure 2.** Forest plots by prevalence: (A) B vs. non-B; (B) O vs. non-O.

6  
7 In the sensitivity analysis, when the study of Liu et al.<sup>17</sup> and Mohammadali et al.<sup>18</sup>, which dominated  
8 the results of the meta-analysis, were orderly removed or both removed at the same time, the pooled risk  
9 estimates were still stable, showing that blood B was associated with a lower risk of HBV infection (Table  
10 2).

### 11 **Publication bias**

12 Funnel plots and Egger's tests were performed to assess publication bias. No obvious evidence of  
13 publication bias was present for A vs. non-A (Figure 3A), B vs. non-B (Figure 3B), and O vs. non-O  
14 (Figure 3C) ( $p = 0.148$ ;  $p = 0.223$ ;  $p = 0.364$ , respectively), while a publication bias of AB vs. non-AB  
15 was observed (Figure 3D) ( $p = 0.002$ ).

16 **Insert Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

### 18 **Discussion**

19 To our knowledge, this was the first meta-analysis of the association between ABO blood groups and HBV  
20 infection. Our meta-analysis results suggested that blood group B was associated with a lower risk of HBV  
21 infection, which was observed in subgroups and still stable in sensitive analyses, giving supportive  
22 evidence that not only statistical association but also biologic association between ABO blood groups and  
23 HBV infection probably exists.

24 As an infectious disease, aside from genetic susceptibility factors, there is the question of whether  
25 exposure to the source of infection is directly related to the risk of infection. People living in higher  
26 endemic areas are at higher risk of exposure to HBV than those living in lower endemic areas, which might  
27 be the reason why the association between ABO blood group and HBV infection was only found in higher

1  
2 1 endemic areas but not in lower endemic areas. Additionally, this association might be partly attributed to the  
3  
4 2 regional factors, due to the high relevance between HBV endemic and region.

5  
6 3 The implementation of universal hepatitis B vaccination program for newborns was started in 1992  
7  
8 4 proposed by WHO. All the selected articles were published between 1970 and 2019, which meant that  
9  
10 5 even in the same country, the prevalence of HBV infection had changed significantly due to the increasing  
11  
12 6 coverage of hepatitis B vaccination. However, no enough information could be extracted from the previous  
13  
14 7 studies to compare the pooled association of ABO blood groups and HBV infection between vaccinated  
15  
16 8 group and unvaccinated group. To partially examine the impact of hepatitis B vaccination on the results,  
17  
18 9 we did subgroup analyses according to the publication year before and after 2010. Subjects in the selected  
19  
20 10 articles were mainly over 18 years old. Thus, subjects in articles published after 2010 were more likely to  
21  
22 11 be vaccinated at the time of birth, while subjects were mostly not vaccinated at birth in the articles  
23  
24 12 published before 2010. We observed the association of blood group B and HBV infection in the articles  
25  
26 13 published before 2010 rather than after 2010. The gradual establishment of an HBV immune barrier in the  
27  
28 14 population may affect the occurrence of the relationship between ABO blood groups and HBV infection.

29  
30 15 Our results found that subjects with blood group O were at higher risk of HBV infection than that of  
31  
32 16 non-O subjects in higher endemic areas, which was consistent with some previous studies of Lao et al.<sup>16</sup>,  
33  
34 17 Liu et al.<sup>17</sup> and Abate et al.<sup>51</sup> That means more measures should be taken to ensure the “universal” group-O  
35  
36 18 blood safety in high endemic areas because of the large unvaccinated population among the main blood  
37  
38 19 donors in current era and the window period for detection among the HBV-infected blood donors.<sup>17</sup>  
39  
40 20 However, this relationship was unobserved in other subgroup analysis, so whether this relationship was  
41  
42 21 true remains to be further explored. Interestingly, our result that blood group B was associated with a lower  
43  
44 22 risk of HBV infection compared with blood group non-B was few reported explicitly by other studies,  
45  
46 23 possibly because of the different analysis methods, such as the different reference of blood group in  
47  
48 24 analysis.

49  
50 25 However, the study of Mohammadali et al.<sup>18</sup>, with the second largest sample size, reported that HBV  
51  
52 26 infection was lower in group-O donors, opposing to the study with the largest sample by Liu et al.,<sup>17</sup>  
53  
54 27 probably due to the different HBV prevalence, geography and ethnicity. Our meta-analysis was  
55  
56 28 inconsistent with the recently meta-analysis, which found that HCC patients might have a lower proportion  
57  
58 29 of O subjects than healthy subjects.<sup>12</sup> The possible explanation for the inconsistency is the long-term and  
59  
60 30 complicated process from HBV infection to the occurrence of HCC. To examine the reliable and stable of

1 the results, we orderly removed the study of Liu et al.<sup>17</sup> or Mohammadali et al.<sup>18</sup>, as well as removed both  
2 of them at the same time. In the sensitive analysis, the relationship between blood group O and HBV  
3 infection might be unstable. However, the inverse relationship between blood group B and HBV infection  
4 was extremely stable. Therefore, we still thought that these findings were worthy of consideration due to  
5 the subgroup analyses, the sensitive analyses and the relatively conservative random effects model.

6 Although the precise role that ABO blood groups play in host susceptibility and HBV infection has yet  
7 to be clarified,<sup>17</sup> associations have been observed that are most likely related to the altered immune  
8 response<sup>16</sup> and systemic inflammatory response,<sup>15</sup> which are associated with different blood group  
9 phenotypes. A previous study has reported that the appearance of intestinal alkaline phosphatase in the  
10 plasma was associated with the ABO blood group and secretor status, which might be due to genetically  
11 determined variations in the proportion of isoenzymes among the different blood types<sup>59</sup>. Our study may  
12 indicate that specific histo-bloodgroup antigen may be a natural resistance factor for HBV infection, and  
13 that probably provides clues for correlative fundamental researches of etiologies and novel therapeutic  
14 targets for HBV. Further studies are warranted to elucidate the association between blood groups and HBV  
15 infection, and the way the blood type influences the process of HBV infection.

16 Meanwhile, several limitations need to be considered. First, although we performed subgroup analyses,  
17 analyses of previous studies have revealed that the heterogeneity cannot be ignored. Second, the analyzed  
18 studies lacked the basic information of the ethnicity data and the prevalence of different HBV genotypes.  
19 Third, few published studies on the association between HBV infection and blood group have controlled  
20 HBV infection related risk factors such as family history of HBV infection, age group, blood transfusion,  
21 and acupuncture, thus we were not able to conduct the corresponding subgroup analyses.

22 In conclusion, blood group B was associated with a lower risk of HBV infection. In the future, more  
23 researches are needed to clarify the precise role of the ABO blood group in HBV infection to address the  
24 global question of HBV infection.

## 26 **Supplementary**

27 Additional file 1: The electronic search strategy for PubMed.

28 Additional file 2: Quality assessment tables.

**Abbreviations** HBV, Hepatitis B virus; RR, risk ratio; CI, confidence interval; VTE, venous thromboembolism; vs., versus; VWF, von Willebrand factor; HBsAg, hepatitis B surface antigen; Rh, rhesus; NOS, Newcastle-Ottawa Scales; AHRQ, Agency for Healthcare Research and Quality.

**Contributions** All authors contributed to this work. ML and JL conceived and designed the study strategy; SZ and WJ independently completed the processes of the article search, article assessment, data extraction, quality assessment, and data analysis; and WJ wrote the manuscript. All authors read and approved the final manuscript.

**Funding** This study was supported by the National Natural Science Foundation of China (Grant No. 71934002, No. 71874003 and No. 81703240).

**Competing interests** The authors declare that they have no competing interests.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Availability of data and material** All data generated or analyzed during this study are included in this published article and its supplementary information files.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution 4.0 Unported (CC BY 4.0) license, which permits others to copy, redistribute, remix, transform and build upon this work for any purpose, provided the original work is properly cited, a link to the licence is given, and indication of whether changes were made. See: <https://creativecommons.org/licenses/by/4.0/>.

## REFERENCES


1. Trepo C, Chan HL, Lok A. Hepatitis B virus infection. *Lancet* 2014; **384**(9959): 2053-63.
2. WHO. Global hepatitis report, 2017. 2017. <http://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/#>.
3. Li B, Tan B, Chen C, Zhao L, Qin L. Association between the ABO blood group and risk of common cancers. *J Evid Based Med* 2014; **7**(2): 79-83.
4. Wang W, Liu L, Wang Z, et al. ABO blood group and esophageal carcinoma risk: from a case-control study in Chinese population to meta-analysis. *Cancer Causes Control* 2014; **25**(10): 1369-77.
5. Cooling L. Blood Groups in Infection and Host Susceptibility. *Clin Microbiol Rev* 2015; **28**(3): 801-70.
6. Alpoim PN, de Barros Pinheiro M, Junqueira DR, et al. Preeclampsia and ABO blood groups: a systematic review and meta-analysis. *Mol Biol Rep* 2013; **40**(3): 2253-61.
7. He M, Wolpin B, Rexrode K, et al. ABO blood group and risk of coronary heart disease in two prospective cohort studies. *Arterioscler Thromb Vasc Biol* 2012; **32**(9): 2314-20.
8. Miao SY, Zhou W, Chen L, Wang S, Liu XA. Influence of ABO blood group and Rhesus factor on breast

- 1  
2 1 cancer risk: a meta-analysis of 9665 breast cancer patients and 244,768 controls. *Asia Pac J Clin Oncol* 2014;  
3 2 **10**(2): 101-8.  
4 3 9. Jenkins PV, O'Donnell JS. ABO blood group determines plasma von Willebrand factor levels: a biologic  
5 4 function after all? *Transfusion* 2006; **46**(10): 1836-44.  
6 5 10. Gallinaro L, Cattini MG, Sztukowska M, et al. A shorter von Willebrand factor survival in O blood group  
7 6 subjects explains how ABO determinants influence plasma von Willebrand factor. *Blood* 2008; **111**(7): 3540-  
8 7 5.  
9 8 11. Anstee DJ. The relationship between blood groups and disease. *Blood* 2010; **115**(23): 4635-43.  
10 9 12. Liu F, Li C, Zhu J, Ren L, Qi X. ABO blood type and risk of hepatocellular carcinoma: a meta-analysis.  
11 10 *Expert Rev Gastroenterol Hepatol* 2018; **12**(9): 927-33.  
12 11 13. Branch DR. Blood groups and susceptibility to virus infection: new developments. *Curr Opin Hematol*  
13 12 2010; **17**(6): 558-64.  
14 13 14. Pare G, Chasman DI, Kellogg M, et al. Novel association of ABO histo-blood group antigen with soluble  
15 14 ICAM-1: results of a genome-wide association study of 6,578 women. *PLoS Genet* 2008; **4**(7): e1000118.  
16 15 15. Zhou Y, Zhou Q, Lin Q, et al. Evaluation of risk factors for extrahepatic cholangiocarcinoma: ABO blood  
17 16 group, hepatitis B virus and their synergism. *Int J Cancer* 2013; **133**(8): 1867-75.  
18 17 16. Lao TT, Sahota DS, Chung MK, Cheung TK, Cheng YK, Leung TY. Maternal ABO and rhesus blood  
19 18 group phenotypes and hepatitis B surface antigen carriage. *J Viral Hepat* 2014; **21**(11): 818-23.  
20 19 17. Liu J, Zhang S, Liu M, Wang Q, Shen H, Zhang Y. Distribution of ABO/Rh blood groups and their  
21 20 association with hepatitis B virus infection in 3.8 million Chinese adults: A population-based cross-sectional  
22 21 study. *J Viral Hepat* 2018; **25**(4): 401-11.  
23 22 18. Mohammadali F, Pourfathollah A. Association of ABO and Rh Blood Groups to Blood-Borne Infections  
24 23 among Blood Donors in Tehran-Iran. *Iran J Public Health* 2014; **43**(7): 981-9.  
25 24 19. Szmunes W, Prince AM, Cherubin CE. Serum hepatitis antigen (SH) carrier state: relation to ABO blood  
26 25 groups. *Br Med J* 1971; **2**(5755): 198-9.  
27 26 20. Szmunes W, Hirsch RL, Prince AM, Levine RW, Harley EJ, Ikram H. Hepatitis B surface antigen in  
28 27 blood donors: further observations. *J Infect Dis* 1975; **131**(2): 111-8.  
29 28 21. Behal R, Jain R, Behal KK, Bhagoliwal A, Aggarwal N, Dhole TN. Seroprevalence and risk factors for  
30 29 hepatitis B virus infection among general population in Northern India. *Arq Gastroenterol* 2008; **45**(2): 137-  
31 30 40.  
32 31 22. WHO. Global health sector strategy on viral hepatitis 2016-2021. 2016.  
33 32 <http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en/>.  
34 33 23. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of  
35 34 nonrandomized studies in meta-analyses. *Eur J Epidemiol* 2010; **25**(9): 603-5.  
36 35 24. Rostom A, Dube C, Cranney A, et al. Agency for Healthcare Research and Quality (US). 2004 Sep.  
37 36 <https://www.ncbi.nlm.nih.gov/books/NBK35156/>.  
38 37 25. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med* 2002; **21**(11): 1539-  
39 38 58.  
40 39 26. World Bank. World Bank list of economies (July 2016). 2016.  
41 40 <http://siteresources.worldbank.org/DATASTATISTICS/Resources/CLASS.XLS>.  
42 41 27. Terrier E, Simonneau M, Jaulmes B. Screening blood donors for Australia antigen carriers at the Broussais  
43 42 hospital. *Vox Sang* 1970; **19**(3): 352-6.  
44 43 28. Leski M, Grivaux C, Courouce-Pauty AM. Australia antigen in hemodialysis and renal transplantation  
45 44 units. *Vox Sang* 1970; **19**(3): 359-68.  
46 45 29. Zuberi SJ, Lodi TZ. Hepatitis B antigen in blood donors in Karachi. 1974. *J Pak Med Assoc* 2004; **54**(8

- 1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60
- 1 Suppl): S39-40.
- 2 30. Vale TG, Thomas HN, Hawkes RA, Kelly A. ABO blood groups and hepatitis B antigen and antibody.
- 3 *Aust N Z J Med* 1974; **4**(1): 1-2.
- 4 31. Moore HH, Campling M, Hart GE. A comparison of hepatitis B antigen and blood groups in African
- 5 donors. *Cent Afr J Med* 1975; **21**(8): 175-6.
- 6 32. Lenka MR, Ghosh E, Bhattacharyya PK. ABO blood groups in relation to hepatitis-B surface antigen
- 7 (Australia antigen). *Trans R Soc Trop Med Hyg* 1981; **75**(5): 688-90.
- 8 33. Nath N, Mushahwar IK, Fang CT, Berberian H, Dodd RY. Antibodies to Delta-Antigen in Asymptomatic
- 9 Hepatitis-B Surface Antigen-Reactive Blood-Donors in the United-States and Their Association with Other
- 10 Markers of Hepatitis-B Virus. *Am J Epidemiol* 1985; **122**(2): 218-25.
- 11 34. Kulkarni AG, Aloowooja FO, Wayo GB. Prevalence of hepatitis B surface antigen in northern Nigerian
- 12 blood donors. *Vox Sang* 1986; **50**(3): 151-3.
- 13 35. Naidu AS, Rajyalakshmi K. Detection of hepatitis B surface antigen among professional blood donors in
- 14 Hyderabad, India. *J Commun Dis* 1986; **18**(3): 215-8.
- 15 36. Sebastian VJ, Bhattacharya S, Ray S, Ahmad MZ. Hepatitis-B surface antigen and VDRL in healthy blood
- 16 donors of Brunei Darussalam. *Singapore Med J* 1989; **30**(6): 568-70.
- 17 37. Zhu C, Zhang H, Xiong J, Gan D. Study on Relationship between ABO Blood-Type and Infection of
- 18 Hepatitis Viruses. *Acta Acad Med Jiangxi* 2002; **42**: 72-3.
- 19 38. Joshi SK, Ghimire GR. Serological prevalence of antibodies to human immunodeficiency virus (HIV) and
- 20 hepatitis B virus (HBV) among healthy Nepalese males--a retrospective study. *Kathmandu Univ Med J* 2003;
- 21 **1**(4): 251-5.
- 22 39. El-Gilany A-H, El-Fedawy S. Bloodborne infections among student voluntary blood donors in Mansoura
- 23 University, Egypt. *East Mediterr Health J* 2006; **12**(6): 742-8.
- 24 40. Rifat-uz-Zaman. Relationship between HBV-markers prevalence and promotive factors among human
- 25 urban population of Bahawalpur district, Pakistan: A cross-sectional study. *Res J Pharmacol* 2009; **3**(1): 7-14.
- 26 41. Dirisu JO, Alli TO, Adegoke AO, Osazuwa F. A Survey of prevalence of serum antibodies to human
- 27 immunodeficiency deficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) among blood
- 28 donors. *N Am J Med Sci* 2011; **3**(1): 35-8.
- 29 42. Saeed Anwar M, Mujtaba Siddiqi G, Haq S, Ghias Khokhar N, Jaffery G. Association of blood group
- 30 types to hepatitis B and hepatitis C virus infection. *Biomedica* 2011; **27**:57-61.
- 31 43. Omar AA, Noor NA, Mahmood JM. The infection with HBV and HCV and their relationship to ABO
- 32 blood group among blood donors. *J Fac Med Baghdad* 2012; **54**(1): 52-6.
- 33 44. Tyagi S, Tyagi A. Possible Correlation of Transfusion Transmitted Diseases with Rh type and ABO Blood
- 34 Group System. *J Clin Diagn Res* 2013; **7**(9): 1930-1.
- 35 45. Sethi B, Kumar S, Butola KS, Mishra JP, Kumar Y. Seroprevalence pattern among blood donors in a
- 36 tertiary health care center. *Internet J Med Update* 2014; **9**(1): 10-5.
- 37 46. Nigam JS, Singh S, Kaur V, Giri S, Kaushal RP. The Prevalence of Transfusion Transmitted Infections in
- 38 ABO Blood Groups and Rh Type System. *Hematol Rep* 2014; **6**(4): 5602.
- 39 47. Zhao Y, Zhang Y, Huang J, Gao J. Clinical analysis of detection of markers related to infectious diseases.
- 40 *Chin J of Nosocomiol* 2014; **24**(14): 3635-7.
- 41 48. Siransy LK, Nanga ZY, Zaba FS, Tufa NY, Dasse SR. ABO/Rh BLOOD GROUPS AND RISK OF HIV
- 42 INFECTION AND HEPATITIS B AMONG BLOOD DONORS OF ABIDJAN, COTE D'IVOIRE. *Eur J*
- 43 *Microbiol Immunol* 2015; **5**(3): 205-9.
- 44 49. Navolan D, Vladareanu S, Ciohat I, et al. Prevalence of HBsAg Carrying Pregnant Women in Romania:

- 1 Demographic and Behavioral Features. *Proceedings of the 49th Annual Scientific Meeting of the European*  
2 *Society for Clinical Investigation* 2015: 249-52.
- 3  
4 50. Bisetegen FS, Bekele FB, Ageru TA, Wada FW. Transfusion-Transmissible Infections among Voluntary  
5 Blood Donors at Wolaita Sodo University Teaching Referral Hospital, South Ethiopia. *Can J Infect Dis Med*  
6 *Microbiol* 2016; (8254343).
- 7  
8 51. Abate M, Wolde T. Seroprevalence of Human Immunodeficiency Virus, Hepatitis B Virus, Hepatitis C  
9 Virus, and Syphilis among Blood Donors at Jigjiga Blood Bank, Eastern Ethiopia. *Ethiop J Health Sci* 2016;  
10 **26**(2): 155-62.
- 11  
12 52. Bharadva S, Vachhani J, Dholakiya S. ABO and Rh association to transfusion transmitted infections  
13 among healthy blood donors in Jamnagar, Gujarat, India. *J Res Med Dent Sci* 2016; **4**(1): 58-62.
- 14  
15 53. Naseri Z, Ghannad MS, Hosseini SM, Roshanaei G, Nejad ASM, Mohammadi A. Evaluation of  
16 Accompaniment of ABO Blood Groups System and Rhesus blood group types with Infection to Hepatitis B  
17 Virus and Hepatitis C Virus in Hamadan, Iran. *Int J of Med Res & Health Sci* 2016; **5**(4): 1-5.
- 18  
19 54. Memon FA, Ujjan ID, Memon AI, Shaikh AR, Rao AR, Naz A. Seroprevalence of transfusion transmitted  
20 infections among different blood group donors at blood bank LUMHS, Hyderabad; 2017.
- 21  
22 55. Batool Z, Durrani SH, Tariq S. Association Of Abo And Rh Blood Group Types To Hepatitis B, Hepatitis  
23 C, Hiv And Syphilis Infection, A Five Year' Experience In Healthy Blood Donors In A Tertiary Care Hospital.  
24 *J Ayub Med Coll Abbottabad* 2017; **29**(1): 90-2.
- 25  
26 56. Ngassaki-Yoka C-D, Ndong JMN, Bisseye C. ABO, Rhesus Blood Groups and Transfusion-transmitted  
27 Infections among Blood Donors in Gabon. *Sudan J Med Sci* 2018; **13**(1): 12-21.
- 28  
29 57. Fu X, Xu C, Cai X, Wu J. Analysis of infection status and clinical significance of infectious diseases  
30 before transfusion. *Chin J Nosocomiol* 2018; **28**(16): 2498-501.
- 31  
32 58. Nkansah C, Serwaa D, Osei-Boakye F, Owusu-Ampomah R. Seroprevalence and trend of hepatitis  
33 among blood donors in a district hospital in Ghana: a nine-year retrospective, descriptive cross-sectional study.  
34 *J J immunoass & immunochem* 2019: 1-13.
- 35  
36 59. Yuan X, Waterworth D, Perry JR, et al. Population-based genome-wide association studies reveal six loci  
37 influencing plasma levels of liver enzymes. *Am J Hum Genet* 2008; **83**(4): 520-8.
- 38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60





**Figure 1.** The process of study selection for the meta-analysis.





Figure 2. Forest plots by prevalence: (A) B vs. non-B; (B) O vs. non-O.



**Figure 3.** Funnel plots: (A) A vs. non-A; (B) B vs. non-B; (C) O vs. non-O; and (D) AB vs. non-AB.

For peer review only - <http://bmjopen.bmj.com/site/about/guidelines.xhtml>

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41

**Additional file 1:**

The electronic search strategy for PubMed:

(((((hepatitis B[MeSH Terms]) OR hepatitis B virus[MeSH Terms]) OR Hepatitis B Surface Antigens[MeSH Terms]) OR hepatitis B[Text Word]) OR hepatitis B virus[Text Word]) OR HBV[Text Word]) OR HBsAg[Text Word]) AND ( "0001/01/01"[PDat] : "2019/11/30"[PDat] ) AND ((((((ABO Blood-Group System[MeSH Terms]) OR Rh-Hr Blood-Group System[MeSH Terms]) OR blood type[Text Word]) OR blood group[Text Word]) OR ABO[Text Word]) OR Rh[Text Word]) OR rhesus[Text Word]) AND ( "0001/01/01"[PDat] : "2019/11/30"[PDat] )

For peer review only

**Additional file 2:****Table S1-1:** Quality assessment for cross-sectional studies by Agency for Healthcare Research and Quality table.

Author	1	2	3	4	5	6	7	8	9	10	11	Total
Terrier, E.1970 <sup>27</sup>	Y	N	N	U	U	Y	/	N	/	Y	Y	4
Leski, M.1970 <sup>28</sup>	Y	N	Y	N	U	Y	N	N	/	Y	Y	5
Szmunn, W.1971 <sup>19</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zuberi, S. J.1974 <sup>29</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Vale, T. G.1974 <sup>30</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Moore, H. H.1975 <sup>31</sup>	Y	N	Y	Y	U	Y	/	N	/	Y	Y	6
Szmunn, W.1975 <sup>20</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Lenka, M. R.1981 <sup>32</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Nath, N.1985 <sup>33</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Kulkarni, A. G.1986 <sup>34</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Naidu, A. S.1986 <sup>35</sup>	Y	N	N	N	U	Y	/	N	Y	Y	Y	5
Sebastian, V. J.1989 <sup>36</sup>	Y	N	N	N	U	Y	/	N	N	Y	Y	4
Zhu, C.2002 <sup>37</sup>	Y	N	Y	Y	U	Y	N	N	N	N	Y	5
Joshi, S. K.2003 <sup>38</sup>	Y	Y	Y	N	U	Y	/	N	/	Y	Y	6
El-Gilany, A-H.2006 <sup>39</sup>	Y	Y	Y	N	U	Y	/	N	Y	N	Y	6
Behal, R.2008 <sup>21</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Rifat-uz-Zaman2009 <sup>40</sup>	Y	Y	Y	/	U	N	/	N	Y	Y	Y	6
Dirisu, J. O.2011 <sup>41</sup>	Y	Y	Y	Y	U	Y	/	N	/	Y	Y	7
Saeed Anwar, M.2011 <sup>42</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Omar, A. A. 2012 <sup>43</sup>	Y	N	Y	N	U	Y	/	N	/	Y	Y	5
Tyagi, S.2013 <sup>44</sup>	Y	Y	Y	N	U	Y	/	N	Y	Y	Y	7
Sethi, B.2014 <sup>45</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Mohammadali, F.2014 <sup>18</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Nigam, J. S.2014 <sup>46</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Zhao, Y.2014 <sup>47</sup>	Y	N	Y	N	U	Y	/	N	Y	Y	Y	6
Siransy, L. K.2015 <sup>48</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8
Navolan, D.2015 <sup>49</sup>	Y	Y	N	N	U	Y	N	N	N	Y	Y	5
Bisetegen, F. S.2016 <sup>50</sup>	Y	Y	Y	N	U	Y	/	N	N	Y	Y	6
Abate, M.2016 <sup>51</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Bharadva, S.2016 <sup>52</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Naseri, Z.2016 <sup>53</sup>	Y	N	Y	Y	U	Y	/	N	Y	Y	Y	7
Memon, F. A.2017 <sup>54</sup>	Y	Y	Y	Y	U	Y	/	N	Y	Y	Y	8
Liu, J.2017 <sup>17</sup>	Y	Y	Y	Y	U	Y	Y	Y	Y	Y	Y	9
Batool, Z.2017 <sup>55</sup>	Y	Y	Y	Y	U	Y	U	N	U	N	Y	6
Ngassaki-Y, C-D.2018 <sup>56</sup>	Y	Y	Y	Y	U	Y	/	N	/	Y	Y	7
Fu, X.2018 <sup>57</sup>	Y	Y	Y	Y	U	Y	Y	N	N	Y	Y	8
Nkansah, C.2019 <sup>58</sup>	Y	Y	Y	Y	U	Y	Y	N	/	Y	Y	8

Y, Yes; N, No; U, Unclear; /, not applicable.

Note:

Item 1: Define the source of information (survey, record review).

- Item 2: List inclusion and exclusion criteria for exposed and unexposed subjects (cases and controls) or refer to previous publications.
- Item 3: Indicate time period used for identifying patients.
- Item 4: Indicate whether or not subjects were consecutive if not population-based.
- Item 5: Indicate if evaluators of subjective components of study were masked to other aspects of the status of the participants.
- Item 6: Describe any assessments undertaken for quality assurance purposes (e.g., test/retest of primary outcome measurements).
- Item 7: Explain any patient exclusions from analysis.
- Item 8: Describe how confounding was assessed and/or controlled.
- Item 9: If applicable, explain how missing data were handled in the analysis.
- Item 10: Summarize patient response rates and completeness of data collection.
- Item 11: Clarify what follow-up, if any, was expected and the percentage of patients for which incomplete data or follow-up was obtained.

**Table S1-2:** Quality assessment for cohort studies by Newcastle-Ottawa Scales table.

Author	Selection	Comparability	Outcome	Total
T. T. Lao 2014 <sup>16</sup>	3	1	3	7

Note:

Selection: 1) Representativeness of the exposed cohort; 2) Selection of the non-exposed cohort; 3) Ascertainment of exposure; 4) Demonstration that outcome of interest was not present at start of study.

Comparability: 1) Comparability of cohorts on the basis of the design or analysis.

Outcome: 1) Assessment of outcome; 2) Was follow-up long enough for outcomes to occur; 3) Adequacy of follow up of cohorts.

**Meta-analysis of Observational Studies in Epidemiology (MOOSE) Checklist**  
**ABO Blood Groups and Hepatitis B Virus Infection: A Systematic Review and**  
**Meta-Analysis**

Criteria	Brief description of how the criteria were handled in the meta-analysis	Page No.
<b>Reporting of background should include</b>		
√ Problem definition	Controversy remains with regard to whether blood group is related to HBV infection and which antigen is a protective or a risk factor.	P4/Line5-6
√ Hypothesis statement	We performed a systematic review and meta-analysis to elucidate the association between ABO blood groups and HBV infection risk.	P4/Line6-7
√ Description of study outcomes	HBV infection	P3/Line6-10
√ Type of exposure or intervention used	ABO blood group	P3/Line11-26
√ Type of study designs used	Systematic Review and Meta-Analysis	P4/Line6
√ Study population	Unrestricted	None
<b>Reporting of search strategy should include</b>		
√ Qualifications of searchers	Two reviewers (SZ and WJ) searched for articles independently.	P4/Line12
√ Search strategy, including time period included in the synthesis and keywords	Available online before December 1, 2019, from five databases including PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central using the following keywords: "hepatitis B" OR "hepatitis B virus" OR "HBV" OR "HBsAg" and "blood type" OR "blood group" OR "ABO" OR "Rh" OR "rhesus".	P4/Line12-15
√ Effort to include all available studies	Highly relevant reference articles were also searched by reviewing the list of references.	P4/Line15-16
√ Databases and registries searched	PubMed, EMBASE, Web of Science, ScienceDirect, and Cochrane Central	P4/Line13-14
√ Search software used, name and version, including special features	We did not employ a search software. Endnote was used to merge retrieved citations.	None
√ Use of hand searching	Highly relevant reference articles were also searched by reviewing the list of references.	P4/Line15-16
√ List of citations located and those excluded, including justifications	Articles were included in the meta-analysis if: (1) the article was a cross-sectional or cohort study; (2) the data of the ABO blood group distribution and HBV infection could	P4/Line19-25

		<p>be extracted to calculate the risk ratio (RR), which meant that the number of HBV-infected and uninfected subjects were reported in each blood group.</p> <p>The exclusion criteria were as follows: (1) the article was not relevant to the subject of the study (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies, where if studies overlapped, we only included the last published; and (4) duplicated studies, where if the same study was found in different databases, we only included the article once.</p>	
√	Method of addressing articles published in languages other than English	There was no limitation of language.	P4/Line16-17
√	Method of handling abstracts and unpublished studies	We did not include unpublished studies. If abstract could provide full information, it was included.	None
√	Description of any contact with authors	When needed, we contacted the original author for the data, but nobody responded to us.	None
<b>Reporting of methods should include</b>			
√	Description of relevance or appropriateness of studies assembled for assessing the hypothesis to be tested	Detailed inclusion and exclusion criteria are described in the paper.	P4/Line19-25
√	Rationale for the selection and coding of data	(1) the basic information of the studies including first author, publication year, journal, survey time, study design; (2) the characteristics of the study population including country, income group, race, population type (e.g., blood donors, patients, general population), sample size, the number of HBV-infected and uninfected subjects, age range, mean age, sex ratio; (3) the outcome measure: the number of HBV-infected and uninfected subjects in each ABO blood group; and (4) the author's general conclusions.	P5/Line3-8
√	Documentation of how data were classified and coded	The prevalence of HBV infection was calculated in each study based on the number of HBV-infected and uninfected subjects. Studies were divided into Caucasian, Asian, and Negroid subgroups depending on the major national race and	P5/Line24-27



		divided into high, upper middle, lower middle and low income groups according to the World Bank list of economies.	
√	Assessment of confounding	Subgroup analyses were performed by HBV prevalence, race, sample size, population, income group, study type, and publication year.	P5/Line23-24
√	Assessment of study quality, including blinding of quality assessors; stratification or regression on possible predictors of study results	The quality of selected cohort studies were assessed using the Newcastle-Ottawa Scales (NOS). The quality of the selected cross-sectional studies were assessed using an 11-item checklist recommended by the Agency for Healthcare Research and Quality (AHRQ).	P5/Line9-13
√	Assessment of heterogeneity	Between-study heterogeneity was evaluated with the $I^2$ statistic. When $I^2 \leq 50\%$ , the included studies were considered to have little heterogeneity; when $I^2 > 50\%$ , the included studies were considered to have substantial heterogeneity.	P5/Line19-22
√	Description of statistical methods in sufficient detail to be replicated	RRs and 95% CIs (A vs. non-A, B vs. non-B, O vs. non-O, AB vs. non-AB) were pooled by using of random-effect models with the estimate of heterogeneity being taken from the Mantel-Haenszel model, and a $p < 0.05$ was deemed significant.	P5/Line17-19
√	Provision of appropriate tables and graphics	Figure 2,3 and Table 2	P9 and Figure 2,3
<b>Reporting of results should include</b>			
√	Graphic summarizing individual study estimates and overall estimate	Table 1 and Table 2	P7 and P9
√	Table giving descriptive information for each study included	Table 1	P7
√	Results of sensitivity testing	Table 2	P9
√	Indication of statistical uncertainty of findings	RR, 95% CI, $I^2$ and P	P9
<b>Reporting of discussion should include</b>			
√	Quantitative assessment of bias	Results of subgroup analyses and sensitive analyses were discussed.	P8-10
√	Justification for exclusion	(1) the article was not relevant to the subject of the study (animal experiments, pathological researches, molecular researches); (2) reviews; (3) overlapped studies, where if studies overlapped, we	P4/Line22-25

		only included the last published; and (4) duplicated studies, where if the same study was found in different databases, we only included the article once.	
√	Assessment of quality of included studies	Table S1-1 and Table S1-2	Additional file 2
<b>Reporting of conclusions should include</b>			
√	Consideration of alternative explanations for observed results	First, although we performed subgroup analyses, analyses of previous studies have revealed that the heterogeneity cannot be ignored. Second, the analyzed studies lacked the basic information of the ethnicity data and the prevalence of different HBV genotypes. Third, few published studies on the association between HBV infection and blood group have controlled HBV infection related risk factors such as family history of HBV infection, age group, blood transfusion, and acupuncture, thus we were not able to conduct the corresponding subgroup analyses.	P12/Line16-21
√	Generalization of the conclusions	In conclusion, blood group B was associated with a lower risk of HBV infection.	P12/Line22
√	Guidelines for future research	In the future, more researches are needed to clarify the precise role of the ABO blood group in HBV infection to address the global question of HBV infection.	P12/Line22-24
√	Disclosure of funding source	This study was supported by the National Natural Science Foundation of China (Grant No. 71934002, No. 71874003 and No. 81703240).	P13/Line9-10